Benzofuran-type lymphocyte-specific tyrosine phosphatase inhibitors, their preparation methods, and applications

By designing benzofuran compounds as LYP inhibitors, the problems of limited structural types and poor selectivity of existing LYP inhibitors have been solved, enabling more effective cancer treatment options.

CN119143705BActive Publication Date: 2026-11-10SHANDONG UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202310658574.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-06-06
Publication Date
2026-11-10
Estimated Expiration
2043-06-06

AI Technical Summary

Technical Problem

The limited structural types and poor selectivity of existing LYP inhibitors restrict their application in cancer treatment.

Method used

A benzofuran-based lymphocyte-specific tyrosine phosphatase inhibitor was developed, and the selectivity and diversity of LYP inhibitors were improved through the design of compounds with specific structures.

Benefits of technology

It enhances the selectivity of LYP inhibitors, provides more structural types, enriches the options for cancer treatment, and has potential anti-cancer effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119143705B_ABST
    Figure CN119143705B_ABST
Patent Text Reader

Abstract

This invention relates to benzofuran-based lymphocyte-specific tyrosine phosphatase inhibitors, their preparation methods, and applications. The compounds have the structure shown in general formula I. The compounds of this invention have good lymphocyte-specific tyrosine phosphatase inhibitory activity and in vivo anticancer activity, and can be used to prepare drugs for the prevention or treatment of cancer. This invention also relates to the pharmaceutical use of compositions of compounds having the structure of general formula I.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to a benzofuran-based lymphocyte-specific tyrosine phosphatase inhibitor, its preparation method, pharmaceutical composition, and pharmaceutical uses, belonging to the field of pharmaceutical technology. Background Technology

[0002] The level of tyrosine phosphorylation in the human body is precisely regulated by protein tyrosine kinase (PTK) and protein tyrosine phosphatases (PTPs). Disorders of the PTK-PTP balance can lead to abnormal tyrosine phosphorylation, which in turn can cause a variety of human diseases, including cancer, metabolic syndrome, and autoimmune diseases.

[0003] Lymphoid-specific tyrosine phosphatase (LYP), an important member of the PTP family, is a negative regulator of the T-cell immune system and is generally considered a contributing factor to various autoimmune diseases. Recent studies have shown that LYP is also closely related to tumorigenesis. The first LYP inhibitor, I-C11, was reported in 2007, and subsequent studies have shown that I-C11 has a certain inhibitory effect on leukemia cells; the recently reported LYP inhibitor L-1 has been shown to inhibit the growth of solid tumors.

[0004] Currently, there is limited research on the anticancer effects of LYP inhibitors, the structures and types of inhibitors are limited, and the selectivity needs to be improved. Therefore, developing selective LYP inhibitors is of great significance for enriching the structural types of LYP inhibitors and for cancer treatment. Summary of the Invention

[0005] This invention provides a benzofuran-based lymphocyte-specific tyrosine phosphatase inhibitor, its preparation method, and its application.

[0006] The present invention further provides pharmaceutical compositions of the compound and its pharmaceutical uses.

[0007] The technical solution of the present invention is as follows:

[0008] I. Benzofuran-type lymphocyte-specific tyrosine phosphatase inhibitors

[0009] A benzofuran-type lymphocyte-specific tyrosine phosphatase inhibitor is a compound having the general formula I, as well as its stereoisomer and a pharmaceutically acceptable salt.

[0010]

[0011] In general formula I, X represents carbon atom, nitrogen atom, and oxygen atom;

[0012] In general formula I, R1 represents a hydrogen atom, a halogen atom, a hydroxyl group, a carboxyl group, an amino group, a nitro group, a cyano group, a guanidinium group, or a C1-C group substituted with 1-3 substituents or unsubstituted. 10 Alkyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, monoheterocyclic groups with 3-6 ring atoms containing 1-2 heteroatoms, monoheterocyclic C1-C6 alkyl groups with 3-6 ring atoms containing 1-2 heteroatoms, C5-C 15 Aryl, C5-C 15 Aryl C1-C6 alkyl, C5-C 15 aryloxy group, C5-C 15 The aryloxy C1-C6 alkyl group comprises a monoheterocyclic aryl group containing 1-2 heteroatoms and having 5-6 ring atoms, or a diheterocyclic aryl group containing 1-4 heteroatoms and having 8-15 ring atoms, wherein the heteroatoms are independently selected from O, S, N, or oxidized S or N; and the substituents are selected from halogen atoms, hydroxyl groups, carboxyl groups, amino groups, nitro groups, cyano groups, guanidinyl groups, and acetal groups.

[0013] In general formula I, R2 represents a hydrogen atom, a halogen atom, a hydroxyl group, a carboxyl group, an amino group, a nitro group, a cyano group, a guanidinium group, or a C1-C group substituted with 1-3 substituents or unsubstituted. 10 Alkyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, substituted secondary amine, monoheterocyclic groups with 3-6 ring atoms containing 1-2 heteroatoms, monoheterocyclic C1-C6 alkyl groups with 3-6 ring atoms containing 1-2 heteroatoms, C5-C 15 Aryl, C5-C 15 Aryl C1-C6 alkyl, C5-C 15 aryloxy group, C5-C 15 The substituent is selected from aryloxy C1-C6 alkyl, monoheterocyclic aryl containing 1-2 heteroatoms and having 5-6 ring atoms, or diheterocyclic aryl containing 1-4 heteroatoms and having 8-15 ring atoms, wherein the substituent is selected from halogen atoms, hydroxyl, carboxyl, amino, nitro, cyano, guanidinyl, C1-C6 alkyl, C3-C8 cycloalkyl, monoheterocyclic group containing 1-2 heteroatoms and having 3-6 ring atoms, monoheterocyclic C1-C6 alkyl containing 1-2 heteroatoms and having 3-6 ring atoms, C5-C6 alkyl, C5-C6 alkyl, C3-C8 cycloalkyl, monoheterocyclic C1-C6 alkyl containing 1-2 heteroatoms and having 3-6 ring atoms, C5-C6 alkyl, C3-C8 cycloalkyl, etc. 15 Aryl, C5-C 15 Aryl C1-C6 alkyl, C5-C 15aryloxy group, C5-C 15 Aryloxy C1-C6 alkyl, a monoheterocyclic aryl group containing 1-2 heteroatoms and having 5-6 ring atoms, or a diheterocyclic aryl group containing 1-4 heteroatoms and having 8-15 ring atoms, wherein the heteroatoms are independently selected from O, S, N, or oxidized S or N;

[0014] In general formula I, R3 represents a hydrogen atom, a halogen atom, a hydroxyl group, a carboxyl group, an amino group, a nitro group, a cyano group, a guanidinyl group, or a C1-C1 group. 10 Alkyl, C1-C6 haloalkyl, C1-C6 alkoxy;

[0015] In general formula I, R4 represents a hydrogen atom, C1-C 10 Alkyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, monoheterocyclic group with 3-6 ring atoms containing 1-2 heteroatoms, monoheterocyclic C1-C6 alkyl group with 3-6 ring atoms containing 1-2 heteroatoms, -(CH2)n1-Ar, -(CH2)n1-Ph-Ar, -(CH2)n1-Ph-O-(CH2)n2-Ar;

[0016] n l Represents integers from 0 to 4;

[0017] n2 represents an integer from 0 to 4;

[0018] Ph stands for phenyl;

[0019] Ar represents C5-C with 1-2 substituents or without substitution. 15 The substituent is selected from aryl, monoheterocyclic aryl containing 1-2 heteroatoms and having 5-6 ring atoms, or diheterocyclic aryl containing 1-4 heteroatoms and having 8-15 ring atoms, wherein the substituent is selected from halogen atoms, hydroxyl, carboxyl, amino, nitro, cyano, guanidinyl, C1-C 10 Alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, wherein the heteroatom is independently selected from O, S, N or oxidized S or N;

[0020] According to a preferred embodiment of the present invention, in general formula I:

[0021] X represents carbon, nitrogen, and oxygen atoms;

[0022] R1 represents hydrogen atom, halogen atom, and nitro group;

[0023] R2 represents a hydrogen atom, a halogen atom, a cyano group, a hydroxyl group, a C1-C6 haloalkyl group, a C1-C6 alkyloxy group, a monoheterocyclic group with 3-6 ring atoms containing 1-2 heteroatoms, a substituted secondary amino group, a C5-C6 monocyclic aryl group, or a monoheterocyclic aryl group with 5-6 ring atoms containing 1-2 heteroatoms. The substituent is selected from halogen atoms, hydroxyl groups, C1-C6 alkyl groups, cyclopropyl groups, monoheterocyclic groups with 3-6 ring atoms containing 1-2 heteroatoms, C5-C6 monocyclic aryl groups, C5-C6 monocyclic aryloxy groups, C1-C6 alkyl groups, or monoheterocyclic aryl groups with 5-6 ring atoms containing 1-2 heteroatoms. The heteroatoms are independently selected from O, S, N, or oxidized S or N.

[0024] R3 represents a hydrogen atom or a halogen atom;

[0025] R4 represents hydrogen atom, C1-C6 alkyl group, -(CH2)n1-Ar, -(CH2)n1-Ph-Ar, -(CH2)n1-Ph-O-(CH2)n2-Ar;

[0026] n l Represents integers from 0 to 4;

[0027] n2 represents an integer from 0 to 4;

[0028] Ph stands for phenyl;

[0029] Ar represents a C5-C6 monocyclic aryl group with 1-2 substituents substituted or unsubstituted, or a monoheterocyclic aryl group with 5-6 ring atoms containing 1-2 heteroatoms, wherein the substituents are selected from halogen atoms, cyano groups, and C1-C6 alkoxy groups, and the heteroatoms are independently selected from O, S, N, or oxidized S or N.

[0030] According to a further preferred embodiment of the present invention, in general formula I:

[0031] X represents carbon and nitrogen atoms;

[0032] R1 represents hydrogen atom, chlorine atom, and nitro group;

[0033] R2 represents a hydrogen atom, chlorine atom, bromine atom, fluorine atom, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, substituted secondary amino group, N-methylpiperazinyl, phenyl or thiophene group with 1-3 substituents or without substitution; the substituent is selected from chlorine atom, hydroxyl, cyclopropyl, ethyl, n-hexyl, 1,3-dioxopentyl, phenyl, morpholinylethyl, phenoxyethyl;

[0034] R3 represents a hydrogen atom and a fluorine atom;

[0035] R4 represents hydrogen atom, methyl, isobutyl, -(CH2)n1-Ar, -(CH2)n1-Ph-Ar, -(CH2)n1-Ph-O-(CH2)n2-Ar;

[0036] n l Represents integers from 0 to 3;

[0037] n2 represents an integer between 0 and 3;

[0038] Ph stands for phenyl;

[0039] Ar represents phenyl or furanyl with 1-2 substituents, or phenyl without substituents, wherein the substituents are selected from chlorine, bromine, fluorine, cyano, or methoxy groups;

[0040] According to the present invention, in a more preferred embodiment of general formula I:

[0041] X represents carbon and nitrogen atoms;

[0042] R1 represents hydrogen atom, chlorine atom, and nitro group;

[0043] R2 represents a chlorine atom, a fluorine atom, a bromine atom, a hydroxyl group, a substituted secondary amino group, a phenyl group, or a thiophene group, wherein the substituent is selected from n-hexyl, morpholinoethyl, or phenoxyethyl.

[0044] R3 represents a hydrogen atom and a fluorine atom;

[0045] R4 represents hydrogen atom, methyl, isobutyl, -(CH2)n1-Ar, -(CH2)n1-Ph-Ar, -(CH2)n1-Ph-O-(CH2)n2-Ar;

[0046] n l Represent 1;

[0047] n2 represents 0 or 1;

[0048] Ph stands for phenyl;

[0049] Ar represents phenyl or furanyl with 1-2 substituents, or without substituents, wherein the substituents are selected from chlorine atoms, bromine atoms, and methoxy groups;

[0050] The most preferred compound of the above general formula I is one of the following:

[0051] 5-((4-chlorophenyl)sulfonamido)benzofuran-2-carboxylic acid (32)

[0052] 5-((4-chloro-N-methylphenyl)sulfonamide)benzofuran-2-carboxylic acid (33)

[0053] 5-((N-([1,1'-biphenyl]-4-ylmethyl)-4-chlorophenyl)sulfonamido)benzofuran-2-carboxylic acid (34)

[0054] 5-((N-([1,1'-biphenyl]-4-ylmethyl)-5-chloro-2,4-difluorophenyl)sulfonamide)benzofuran-2-carboxylic acid (35)

[0055] 5-((N-([1,1'-biphenyl]-4-ylmethyl)-6-chloropyridine)-3-sulfonyl)benzofuran-2-carboxylic acid (36)

[0056] 5-((N-([1,1'-biphenyl]-4-ylmethyl)-4-(thiophen-2-yl)phenyl)sulfonamide)benzofuran-2-carboxylic acid (37)

[0057] 5-((4-chloro-N-isobutyl-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid (38)

[0058] 5-((N-benzyl-4-chloro-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid (39)

[0059] 5-((4-chloro-N-((4'-chloro-[1,1'-biphenyl]-4-yl)methyl)-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid (40)

[0060] 5-((4-chloro-N-((4'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid (41)

[0061] 5-((N-([1,1'-biphenyl]-4-ylmethyl)-4-chloro-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid (42)

[0062] 5-((N-([1,1'-biphenyl]-4-ylmethyl)-4-hydroxy-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid (43)

[0063] 5-((4-chloro-3-nitro-N-(4-phenoxybenzyl)phenyl)sulfonamide)benzofuran-2-carboxylic acid (44)

[0064] 5-((4-chloro-N-((2',3'-dichloro-[1,1'-biphenyl]-4-yl)methyl)-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid (45)

[0065] 5-((N-([1,1'-biphenyl]-4-ylmethyl)-4-bromophenyl)sulfonamide)benzofuran-2-carboxylic acid (46)

[0066] 5-([1,1'-biphenyl]-4-sulfonamide)benzofuran-2-carboxylic acid (47)

[0067] 5-(N-methyl-[1,1'-biphenyl]-4-sulfonamide)benzofuran-2-carboxylic acid (48)

[0068] 5-(N-([1,1'-biphenyl]-4-ylmethyl)-[1,1'-biphenyl]-4-sulfonamido)benzofuran-2-carboxylic acid (49)

[0069] 5-(N-([1,1'-biphenyl]-3-ylmethyl)-[1,1'-biphenyl]-4-sulfonamido)benzofuran-2-carboxylic acid (50)

[0070] 5-(N-((4'-chloro-[1,1'-biphenyl]-4-yl)methyl)-[1,1'-biphenyl]-4-sulfonamide)benzofuran-2-carboxylic acid (51)

[0071] 5-(N-((4'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-[1,1'-biphenyl]-4-sulfonamide)benzofuran-2-carboxylic acid (52)

[0072] 5-(N-(4-(furan-2-yl)benzyl)-[1,1'-biphenyl]-4-sulfonamido)benzofuran-2-carboxylic acid (53)

[0073] 5-(N-(4-(benzyloxy)benzyl)-[1,1'-biphenyl]-4-sulfonamide)benzofuran-2-carboxylic acid (54)

[0074] 5-(N-(4-phenoxybenzyl)-[1,1'-biphenyl]-4-sulfonamide)benzofuran-2-carboxylic acid (55)

[0075] 5-((N-([1,1'-biphenyl]-4-ylmethyl)-3'-hydroxy-[1,1'-biphenyl])-4-sulfonamide)benzofuran-2-carboxylic acid (56)

[0076] 5-((N-benzyl-4-(hexylamino)-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid (57)

[0077] 5-((N-([1,1'-biphenyl]-4-ylmethyl)-4-(hexylamino)-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid (58)

[0078] 5-((N-methyl-4-((2-morpholinoethyl)amino)-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid (59)

[0079] 5-((N-benzyl-3-nitro-4-((2-phenoxyethyl)amino)phenyl)sulfonamido)benzofuran-2-carboxylic acid (60)

[0080] 5-((N-(3-bromobenzyl)-3-nitro-4-((2-phenoxyethyl)amino)phenyl)sulfonamide)benzofuran-2-carboxylic acid (61)

[0081] The preferred compounds listed above are numbered in parentheses to correspond to the reaction routes below and the compound structures in Table 1. Invention Details

[0083] The terms and definitions used in this article have the following meanings:

[0084] The "halogen atom" mentioned in this invention includes fluorine atoms, chlorine atoms, bromine atoms, and iodine atoms;

[0085] The "C" described in this invention 1-10 "Alkyl" refers to a straight-chain or branched alkyl group derived from an alkane containing 1 to 10 carbon atoms by removing one hydrogen atom, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, neopentyl, 1-ethylpropyl, n-hexyl, isohexyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2 -Dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, heptyl, octyl, nonyl, and decyl. Preferably C1-C6 alkyl, the term "C1-C6 alkyl" refers to specific examples containing 1 to 6 carbon atoms in the above examples;

[0086] The "C" described in this invention 3-8 "Cycloalkyl" refers to a cyclic alkyl group derived from an alkane with 3 to 8 carbon atoms by removing one hydrogen atom, such as cyclopropyl, cyclobutyl, 1-methylcyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, etc. C3-C6 cycloalkyl groups are preferred.

[0087] The term "mono-heterocyclic group" as used in this invention refers to a cyclic alkyl or alkenyl group containing 1-3 heteroatoms and having a ring atom number of 3-6, such as: ethylene oxide, dioxacyclopropane, thiocyclopropane, aziroxacyclopropane, 2H-aziroxacyclopropane, diaziroxacyclopropane, 3H-diazacyclopropenyl, oxaziroxacyclopropane, oxaziroxacyclobutane, 1,2-dioxacyclobutane, thiocyclobutane, 1,2-dithiocyclobutenyl, aziroxacyclobutane, 1,2-diazacyclobutenyl, aziroxacyclobutadienyl, 1,2-diazacyclobutenyl, furanyl, tetrahydrofuranyl, thiophene, 2,5-dihydrothiophene, tetrahydrothiophene, pyrrole, dihydropyrrole, pyrroleyl, 1,3-dioxacyclopentane. 1,3-Dioxacyclopenten-2-one, 1,2-Dithiocyclopentenyl, 1,3-Dithiocyclopentyl, imidazolyl, 4,5-Dihydroimidazolyl, imidazolyl, pyrazolyl, 4,5-Dihydropyrazolyl, pyrazolyl, oxazolyl, 4,5-Dihydrooxazolyl, isoxazolyl, 4,5-Dihydroisooxazolyl, 2,3-Dihydroisooxazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, thiazolyl, 4,5-Dihydrothiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, 2H-pyranyl, 2H-pyran-2-one, 3,4 -Dihydro-2H-pyranyl, 4H-pyranyl, tetrahydropyranyl, 4H-pyran-4-keto, pyridyl, 2-pyridoneyl, 4-pyridoneyl, piperidinyl, 1,4-dioxazinyl, 1,4-dithionecyclohexadienyl, 1,4-oxothionecyclohexadienyl, 1,4-dioxazinyl, 1,3-dioxazinyl, 1,3-oxothionecyclohexaneyl, 2H-1,2-oxazinyl, 4H-1,2-oxazinyl, 6H-1,2-oxazinyl, 2H-1,3-oxazinyl, 4H-1,3-oxazinyl, 6H-1,3-oxazinyl, 2H-1,4-oxazinyl, 4H-1,4-oxazinyl, 5,6-dihydro-4H-1,3-oxazinyl, morphoyl Phinyl, 2H-1,3-thiazinyl, 4H-1,3-thiazinyl, 5,6-dihydro-4H-1,3-thiazinyl, 6H-1,3-thiazinyl, 2H-1,4-thiazinyl, 4H-1,4-thiazinyl, pyridinyl, pyrazinyl, piperazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,4,5-tetraazinyl, oxetane-heptanetrienyl, thiohepanetrienyl, 1,4-dioxetane-octanetrienyl, azirne-heptanetrienyl, 1,2-diazahepanetrienyl, 1,3-diazahepanetrienyl, 1,4-diazahepanetrienyl, azirne-octanetrienyl, 1,4-dihydro-1,4-diazahepanetrienyl, etc. Preferably, a monoheterocyclic group containing 1-2 heteroatoms and having 5-6 ring atoms is used;

[0088] In this invention, "aryl" refers to a substituent containing an aromatic ring, such as phenyl or benzyl, which may optionally be fused with a cycloalkyl group. Preferably, the aryl group contains 5-15 carbon atoms;

[0089] The "heteroaryl" described in this invention is an aromatic heterocycle, which can be a monocyclic or bicyclic group. They contain one or more heteroatoms, preferably 1-2 heteroatoms, wherein the heteroatoms are independently selected from O, S, and N;

[0090] The "arylalkyl" mentioned in this invention refers to an aryl group linked by a C1-C6 alkylene group;

[0091] In this invention, "alkoxy" and "aryloxy" respectively represent the groups -O-alkyl and -O-aryl;

[0092] The term "haloalkyl" as used in this invention refers to an alkyl group substituted with one or more halogen atoms;

[0093] The "integers from 0 to 4" mentioned in this invention refer to 0, 1, 2, 3, and 4;

[0094] The compound of general formula I of the present invention can be prepared into a pharmaceutically acceptable salt by known methods, wherein the salt is a salt prepared by mixing the compound of formula I with an acid or a base;

[0095] Suitable acid addition salts are formed from acids that form non-toxic salts. Representative acid addition salts include, but are not limited to, acetates, adipicates, alginates, citrates, aspartate, benzoates, benzenesulfonates, bisulfates, bicarbonates, butyrates, camphorates, camphorsulfonates, carbonates, citrates, digluconate, glycerol phosphates, hemisulfates, heptarates, hexanoates, formates, fumarates, gluconates, glucurons, glutamates, hydrochlorides, hydrobromide, hydroiodates, and isethionate. Lactate, maleate, malate, malonate, methanesulfonate, nicotate, 2-naphthalenesulfonate, nicotinate, nitrate, orotate, oxalate, palmitate, pyrate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, sucrose, stearate, succinate, sulfate, tartrate, thiocyanate, phosphate, hydrogen phosphate, dihydrogen phosphate, p-toluenesulfonate, trifluoroacetate, and undecanoate;

[0096] Base addition salts can be prepared in situ during the final separation and purification of compounds by reacting the carboxylic acid-containing moiety with a suitable base (such as, but not limited to, hydroxides, carbonates, or bicarbonates of pharmaceutically acceptable metal cations) or with ammonia or organic primary, secondary, or tertiary amines. Pharmaceutically acceptable salts include, but are not limited to, alkali metal or alkaline earth metal-based cations, such as, but not limited to, lithium, sodium, potassium, calcium, magnesium, and aluminum salts, as well as non-toxic quaternary ammonium and amine cations, including ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, etc. Other representative organic amines that can be used to form base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, piperazine, etc.

[0097] As used herein, "stereoisomer" refers to all possible stereoisomers of the compounds of this invention or their physiologically antitumor compounds. Unless otherwise specified, the chemical nomenclature of the compounds involved in this invention includes mixtures of all possible stereochemical forms, comprising all enantiomers and diastereomers of the basic structural molecule, as well as substantially pure single isomers of the compound, i.e., containing less than 10%, preferably less than 5%, particularly less than 2%, and most preferably less than 1% of other isomers. All stereoisomers of the peptide compounds of this invention are clearly included within the scope of this invention;

[0098] Compounds of general formula I may also exist in other protected forms or as antitumor compounds, which are obvious to those skilled in the art and should all be included within the scope of this invention.

[0099] The substituents described above can also be replaced by one or more substituents. Such substituents include those listed in C. Hansch and A. Leo, Substituent Constants for Correlation Analysis in Chemistry and Biology (1979); preferred substituents include alkyl, alkenyl, alkoxy, hydroxyl, nitro, amino, aminoalkyl, cyano, halogen, carboxyl, thio, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, imino, hydroxyalkyl, aryloxy, arylalkyl, and combinations thereof;

[0100] The compounds of this invention can be formulated into any pharmaceutical preparation using methods known in the art, for administration to patients requiring such treatment via oral, parenteral, rectal, or pulmonary routes. For oral administration, they can be formulated into conventional solid dosage forms such as tablets, capsules, pills, and granules, or into oral liquid dosage forms such as oral solutions, oral suspensions, and syrups. When formulating oral dosage forms, suitable fillers, binders, disintegrants, lubricants, etc., can be added. For parenteral administration, they can be formulated into injectable preparations, including injection solutions, sterile powders for injection, and concentrated solutions for injection. Injectable preparations can be manufactured using conventional methods in the existing pharmaceutical field. When preparing injectable preparations, excipients may not be added, or suitable excipients may be added depending on the properties of the drug. For rectal administration, they can be formulated into suppositories, etc. For pulmonary administration, they can be formulated into inhalers or sprays, etc.

[0101] The dosage and frequency of administration of the compounds of the present invention may be adjusted based on the judgment of a clinician or pharmacist, taking into account factors such as the patient's age, health condition and size, and the severity of the condition to be treated. Generally, the total daily dose of the compounds of the present invention ranges from about 0.1 to about 2000 mg per day, although variations may occur as necessary depending on the therapeutic purpose, the patient, and the route of administration. In one embodiment, the dose is about 1 to about 200 mg / day, administered in a single dose or in 2-4 separate doses. In another embodiment, the dose is about 10 to about 2000 mg / day, administered in a single dose or in 2-4 separate doses. In yet another embodiment, the dose is about 100 to about 2000 mg / day, administered in a single dose or in 2-4 separate doses. In yet another embodiment, the dose is about 500 to about 2000 mg / day, administered in a single dose or in 2-4 separate doses. When the compounds of the present invention, their pharmaceutically acceptable salts, esters, or solvates, or their prodrugs or isomers, are used in combination with other therapeutically active substances, they can be administered simultaneously, separately, or sequentially to form pharmaceutical compositions with a single route of administration. The dosage of the other therapeutically active substances used in combination can be based on clinically used amounts and can be appropriately selected according to the target population, route of administration, disease, combination, etc. There are no particular restrictions on the administration methods of the other therapeutically active substances, as long as the compounds of the present invention are combined with the other therapeutically active substances at the time of administration.

[0102] "Pharmaceutical composition" refers to a preparation containing a therapeutically significant amount of an active pharmaceutical ingredient, prepared in a form suitable for administration to a patient. Therefore, the preparation does not contain any one or more components in amounts that a reasonably prudent medical practitioner would find unsuitable for administration to a general population. In many cases, such pharmaceutical compositions are sterile preparations.

[0103] The specific temperature range of "room temperature" in this invention is 25-30°C.

[0104] II. Preparation method of benzofuran-based lymphocyte-specific tyrosine phosphatase inhibitors

[0105] Preparation steps of a benzofuran-based lymphocyte-specific tyrosine phosphatase inhibitor:

[0106] Ethyl 5-nitrobenzofuran-2-carboxylate was reduced by iron powder to generate intermediate 2. Under pyridine conditions, intermediate 2 reacted with substituted sulfonyl chloride to obtain intermediates 3-9. Subsequently, intermediates 3-9 under the action of sodium hydride under N-alkylation reaction with haloalkanes to obtain intermediates 10-31. Finally, under different deethylation protection reaction conditions, the final products 32-55 were obtained.

[0107] Intermediate 23 reacted with 3-hydroxyphenylboronic acid via a Suzuki reaction to yield final product 56;

[0108] Intermediates 16-18 undergo nucleophilic substitution with substituted primary amines, followed by deethyl ester protection under sodium hydroxide conditions to give final products 57-61; the synthetic route is as follows:

[0109] Synthetic route

[0110]

[0111] Reagents and reaction conditions: (a) iron powder, ammonium chloride, ethanol, room temperature; (b) substituted sulfonyl chloride, pyridine, room temperature; (c) haloalkanes, sodium hydride, N,N-dimethylformamide, room temperature; (d) sodium hydroxide, water, tetrahydrofuran, room temperature; (e) potassium hydroxide, tert-butanol, 100°C; (f) 3-hydroxyphenylboronic acid, tetra(triphenylphosphine palladium), potassium carbonate, 1,4-dioxane, water, nitrogen protection, reflux; (g)(i) substituted primary amine, triethylamine, acetonitrile, reflux; (ii) sodium hydroxide, water, tetrahydrofuran, room temperature;

[0112] The substituted sulfonyl chlorides are p-4-chlorobenzenesulfonyl chloride, 5-chloro-2,4-difluorobenzenesulfonyl chloride, 6-chloropyridinesulfonyl chloride, 4-thiophenesulfonyl chloride, 4-chloro-3-nitrobenzenesulfonyl chloride, 4-bromobenzenesulfonyl chloride, 4-chlorobenzenesulfonyl chloride, and p-biphenylsulfonyl chloride; the halogenated hydrocarbons are iodomethane, iodoisobutane, benzyl bromide, 2-bromobenzene bromide, 4-phenylbenzene bromide, 3-phenylbenzene bromide, 4'-chloro4-phenylbenzene bromide, 4'-methoxy4-phenylbenzene bromide, 4-furanylbenzene bromide, 4-benzyloxybenzene bromide, and 4-phenoxybenzene bromide; the substituted primary amines are n-hexylamine, N-(2-aminoethyl)morpholine, and 2-phenoxyethylamine;

[0113] The structures of the target compounds in the synthetic route are shown in Table 1 below:

[0114] Table 1. Structure of the target compound

[0115]

[0116]

[0117]

[0118] The specific steps for operating the compound will be described in detail in the examples.

[0119] Those skilled in the art can modify the above steps to increase the yield. They can design synthetic routes based on basic knowledge in the field, such as selecting reactants, reaction solvents, and reaction temperatures. They can also improve the yield by using various protecting groups to avoid side reactions. For example, T. Green Protecting Groups in Organic Synthesis can be found in these conventional protection methods.

[0120] III. Application of Benzofuran-based Lymphocyte-Specific Tyrosine Phosphatase Inhibition

[0121] This invention also provides the application of benzofuran-type lymphocyte-specific tyrosine phosphatase inhibition in the preparation of drugs for the prevention or treatment of cancer.

[0122] Furthermore, the present invention also includes a pharmaceutical composition suitable for oral administration to mammals, comprising any compound of general formula I above, a pharmaceutically acceptable carrier, and optionally comprising one or more pharmaceutically acceptable excipients.

[0123] Furthermore, the present invention also includes a pharmaceutical composition suitable for parenteral administration to mammals, comprising any compound of general formula I above, a pharmaceutically acceptable carrier, and optionally containing one or more pharmaceutically acceptable excipients.

[0124] A pharmaceutical composition comprising any compound of general formula I, its stereoisomer or a pharmaceutically acceptable salt thereof, and one or more therapeutically active substances, said therapeutically active substances being selected from targeted antitumor drugs or chemotherapeutic agents, monoclonal antibody drugs, and immunotherapy.

[0125] The biological activity of the compound was evaluated by testing both its enzyme-inhibiting activity and its in vivo antitumor activity.

[0126] The inhibitory activity of compounds against LYP was evaluated using a colorimetric method. In evaluating the in vitro inhibitory activity against LYP, the simulated substrate, disodium p-nitrophenyl phosphate, was co-incubated with LYP, causing the substrate to dephosphate group and transform into the yellow product p-nitrophenol, which exhibited maximum absorbance at 405 nm under alkaline conditions. The absorbance intensity was proportional to the LYP inhibitory effect of the test compound. Data were processed using PrismGraphPad software to calculate the inhibition rate and IC50 of different target compounds against LYP. 50 value.

[0127] The in vivo antitumor activity of the compound was studied using MC38 tumor-bearing mice as an animal model. MC38 cells were subcutaneously injected into C57BL / 6J mice to establish the model. The compound was then administered via gavage. The in vivo anticancer effect of the compound was evaluated by comparing tumor growth in the drug-treated group and the control group.

[0128] In vitro enzyme inhibition experiments showed that more than half of the compounds in this invention exhibited good LYP inhibitory activity, IC50... 50 Values ​​less than 20 μM, with IC50 values ​​for compounds 41, 50, 54, and 56 being relatively low. 50 The concentration was less than 4 μM. In vivo antitumor studies showed that, compared to the control group, compounds 41 and 54 inhibited MC38 tumor growth after treatment. Therefore, some compounds in this invention possess good LYP inhibitory activity and in vivo antitumor activity, showing great promise for development and potentially guiding the discovery of novel, highly effective selective inhibitors of lymphocyte-specific tyrosine phosphatase and antitumor active molecules. Attached Figure Description

[0129] Figure 1 The results show the in vivo antitumor effects of the active compounds; among them, (A) changes in body weight of mice in each group during administration of 41 and 54; (B) tumor growth in mice in each group during administration of 41 and 54; and (C) tumor weight after treatment with 41 and 54. Detailed Implementation

[0130] The present invention will be further described below with reference to embodiments, but is not limited thereto.

[0131] Example 1. Ethyl 5-aminobenzofuran-2-carboxylate (2)

[0132] Ethyl 5-nitrobenzofuran-2-carboxylate 1 (12.50 g, 53.14 mmol), iron powder (21.50 g, 398.50 mmol), and ammonium chloride (14.00 g, 265.70 mmol) were added to ethanol and mechanically stirred at room temperature for 6–12 hours. After adding diatomaceous earth and filtering to remove the iron powder, the solution was concentrated. During the process, yellow needle-like crystals precipitated. The solution was filtered to obtain intermediate 2, yield: 92%, melting point: 58–60 °C.1 H NMR (400MHz, DMSO-d6) δ7.51(s,1H),7.37(d,J=8.5Hz,1H),6.87–6.76(m,2H),5.06(s,2H),4.33(q,J=7.1Hz,2H),1.32(t,J=7.1Hz,3H).

[0133] 5-((4-chlorophenyl)sulfonamido)benzofuran-2-carboxylic acid ethyl ester (3)

[0134] Intermediate 2 (2.95 g, 14.40 mmol) and 4-chlorobenzenesulfonyl chloride (2.53 g, 12.00 mmol) were dissolved in pyridine (40.0 mL) and stirred at room temperature for 6 h. The reaction mixture was acidified with 3 M hydrochloric acid solution, extracted with ethyl acetate solution, washed twice with saturated brine, dried over anhydrous magnesium sulfate, and filtered. The crude product was purified by Flash column chromatography to give 3.60 g of white solid, yield: 79%, melting point: 132–134 °C. 1 H NMR (400MHz, CDCl3) δ7.71–7.66(m,2H),7.62(s,1H),7.48(d,J=2.2Hz,1H),7.43(d,J=8.3Hz,2 H),7.40–7.35(m,2H),7.15(dd,J=9.0,2.2Hz,1H),4.44(q,J=7.1Hz,2H),1.42(t,J=7.1Hz,3H).

[0135] 5-((5-chloro-2,4-difluorophenyl)sulfonamide)benzofuran-2-carboxylic acid ethyl ester (4)

[0136] For specific procedures, refer to the synthesis of intermediate 3, with a yield of 65%. 1 H NMR (400MHz, DMSO-d6) δ10.80(s,1H),7.94(t,J=7.5Hz,1H),7.81(t,J=9.6Hz,1H),7.73(s,1H),7.67(d,J= 8.9Hz, 1H), 7.54 (d, J = 2.1Hz, 1H), 7.26 (dd, J = 8.9, 2.2Hz, 1H), 4.35 (q, J = 7.1Hz, 2H), 1.32 (t, J = 7.1Hz, 3H).

[0137] 5-((6-chloropyridine)-3-sulfonamide)benzofuran-2-carboxylic acid ethyl ester (5)

[0138] For specific procedures, refer to the synthesis of intermediate 3, with a yield of 74% and a melting point of 180–182℃. 1H NMR (400MHz, DMSO-d6) δ10.61(s,1H),8.68(d,J=2.4Hz,1H),8.08(dd,J=8.4,2.6Hz,1H),7.77–7.65(m ,3H),7.55(d,J=2.1Hz,1H),7.23(dd,J=8.9,2.2Hz,1H),4.36(q,J=7.1Hz,2H),1.33(t,J=7.1Hz,3H).

[0139] 5-((4-(thiophen-2-yl)phenyl)sulfonamide)benzofuran-2-carboxylic acid ethyl ester (6)

[0140] For specific procedures, refer to the synthesis of intermediate 3, with a yield of 89% and a melting point of 180–183°C. 1 H NMR (400MHz, DMSO-d6) δ10.36(s,1H),7.81(d,J=8.5Hz,2H),7.75–7.70(m,3H),7.68–7.61(m,3H),7.53(d,J=2. 0Hz, 1H), 7.24 (dd, J=8.9, 2.2Hz, 1H), 7.17 (dd, J=4.9, 3.8Hz, 1H), 4.33 (q, J=7.1Hz, 2H), 1.31 (t, J=7.1Hz, 3H).

[0141] 5-((4-chloro-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid ethyl ester (7)

[0142] For specific procedures, refer to the synthesis of intermediate 3, yield 40%, melting point: 138–140℃. 1 H NMR (400MHz, DMSO-d6) δ10.63(s,1H),8.39(d,J=2.0Hz,1H),7.96(d,J=8.5Hz,1H),7.91(dd,J=8.5,2.1Hz,1H),7.74(s,1 H),7.67(d,J=8.9Hz,1H),7.55(d,J=2.1Hz,1H),7.24(dd,J=8.9,2.2Hz,1H),4.35(q,J=7.1Hz,2H),1.33(t,J=7.1Hz,3H).

[0143] 5-((4-bromophenyl)sulfonamide)benzofuran-2-carboxylic acid ethyl ester (8)

[0144] For specific procedures, refer to the synthesis of intermediate 3, with a yield of 91% and a melting point of 98–101℃. 1H NMR (400MHz, DMSO-d6) δ10.39(s,1H),8.59(d,J=4.2Hz,1H),7.82–7.71(m,3H),7.64(d,J=8.6Hz,2H),7.52(d,J= 2.0Hz, 1H), 7.39 (dd, J=7.5, 5.7Hz, 1H), 7.22 (dd, J=8.9, 2.1Hz, 1H), 4.35 (q, J=7.1Hz, 2H), 1.32 (t, J=7.1Hz, 3H).

[0145] 5-([1,1'-biphenyl]-4-sulfonamide)benzofuran-2-carboxylic acid ethyl ester (9)

[0146] For specific procedures, refer to the synthesis of intermediate 3, with a yield of 72% and a melting point of 139–142℃. 1 H NMR (400MHz, DMSO-d6) δ10.39(d,J=1.7Hz,1H),7.81(q,J=8.8Hz,4H),7.73–7.65(m,3H),7.63(d,J=8.9Hz,1H),7.56(d,J =1.8Hz,1H),7.44(ddd,J=10.9,9.6,5.8Hz,3H),7.26(dt,J=9.0,2.0Hz,1H),4.33(q,J=7.0Hz,2H),1.31(t,J=7.1Hz,3H).

[0147] 5-((4-chloro-N-methylphenyl)sulfonamide)benzofuran-2-carboxylic acid ethyl ester (10)

[0148] Intermediate 3 (3.77 g, 10.0 mmol) and sodium hydride (0.48 g, 12.0 mmol) were dissolved in N,N-dimethylformamide (35 mL) and stirred at room temperature for 15 min. Iodomethane (0.75 mL, 12.0 mmol) was added to the reaction system, and the mixture was stirred at 80 °C for 2 h. After cooling to room temperature, the reaction system was quenched with water and extracted with ethyl acetate. The ethyl acetate was washed twice with saturated brine, dried over anhydrous magnesium sulfate, and filtered. The solvent was removed under reduced pressure to obtain a yellow crude product, which was then purified by recrystallization from a mixture of ethyl acetate and petroleum ether to give 3.39 g of a white solid, yield: 86%, melting point: 120–122 °C. 1H NMR(400MHz, DMSO-d6)δ7.76–7.70(m,2H),7.68–7.64(m,2H),7.55(d,J=2.2Hz,1H),7.53–7.49 (m,2H),7.25(dd,J=8.9,2.3Hz,1H),4.37(q,J=7.1Hz,2H),3.20(s,3H),1.34(t,J=7.1Hz,3H).

[0149] 5-((N-([1,1'-biphenyl]-4-ylmethyl)-4-chloro-3-nitrophenyl)sulfonamide) ethyl benzofuran-2-carboxylate (11)

[0150] For specific procedures, refer to the synthesis of intermediate 10. Yield: 73%, melting point: 180–183℃. 1 H NMR (400MHz, DMSO-d6) δ7.71(t,J=5.3Hz,3H),7.66(d,J=8.8Hz,3H),7.60(d,J=1.3Hz,1H),7.59–7.54(m,4H),7.42(t,J=7.6 Hz,2H),7.33(dd,J=13.7,7.7Hz,3H),7.23(dd,J=8.9,2.2Hz,1H),4.90(s,2H),4.34(q,J=7.1Hz,2H),1.31(t,J=7.1Hz,3H).

[0151] 5-((N-([1,1'-biphenyl]-4-ylmethyl)-5-chloro-2,4-difluorophenyl)sulfonamide) ethyl benzofuran-2-carboxylate (12)

[0152] For specific procedures, refer to the synthesis of intermediate 10. Yield: 76%, melting point: 174–176℃. 1 H NMR (400MHz, DMSO-d6) δ7.94(t,J=9.6Hz,1H),7.88(t,J=7.5Hz,1H),7.68(dd,J=8.8,2.9Hz,3H),7.59(t,J=8 .2Hz,4H),7.42(t,J=7.6Hz,2H),7.38–7.30(m,4H),5.00(s,2H),4.34(q,J=7.1Hz,2H),1.31(t,J=7.1Hz,3H).

[0153] 5-((N-([1,1'-biphenyl]-4-ylmethyl)-6-chloropyridine)-3-sulfonyl)benzofuran-2-carboxylic acid ethyl ester (13)

[0154] For specific procedures, refer to the synthesis of intermediate 10. Yield: 62%, melting point: 196–198℃. 1 H NMR (400MHz, DMSO-d6) δ8.70(d,J=2.3Hz,1H),8.05(dd,J=8.4,2.6Hz,1H),7.80(d,J=8.4Hz,1H),7.68(d,J=9.7Hz,2H),7.64(d,J=2.0Hz,1H),7.5 8(t,J=8.4Hz,4H),7.42(t,J=7.6Hz,2H),7.38–7.32(m,3H),7.30(dd,J=8 .8,2.1Hz,1H),4.95(s,2H),4.34(q,J=7.1Hz,2H),1.31(t,J=7.1Hz,3H).

[0155] 5-((N-([1,1'-biphenyl]-4-ylmethyl)-4-(thiophen-2-yl)phenyl)sulfonamide) ethyl benzofuran-2-carboxylate (14)

[0156] For specific procedures, refer to the synthesis of intermediate 10. Yield: 66%, melting point: 201–203℃. 1 H NMR (400MHz, DMSO-d6) δ7.91(d,J=8.4Hz,2H),7.76(d,J=3.5Hz,1H),7.73(d,J=5.0Hz,1H),7.70–7.64(m,4H),7.62–7.53(m,5 H),7.37(ddd,J=20.3,14.9,7.3Hz,5H),7.25(td,J=8.9,3.5Hz,2H),4.92(s,2H),4.34(q,J=7.1Hz,2H),1.30(t,J=7.1Hz,3H).

[0157] 5-((4-chloro-N-isobutyl-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid ethyl ester (15)

[0158] For specific procedures, refer to the synthesis of intermediate 10. Yield: 34%, melting point: 150–153℃. 1H NMR (400MHz, DMSO-d6) δ8.23(d,J=2.1Hz,1H),7.97(d,J=8.5Hz,1H),7.77–7.71(m,3H),7.65(d,J=2.1Hz,1H),7.27(dd,J=9 .0,2.1Hz,1H),4.38(q,J=7.1Hz,2H),3.45(d,J=7.3Hz,2H),1.50–1.41(m,1H),1.34(t,J=7.1Hz,3H),0.88(d,J=6.6Hz,6H).

[0159] 5-((N-benzyl-4-chloro-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid ethyl ester (16)

[0160] For specific procedures, refer to the synthesis of intermediate 10. Yield: 54%, melting point: 118–121℃. 1 H NMR (400MHz, DMSO-d6) δ8.36(d,J=2.1Hz,1H),8.01(d,J=8.5Hz,1H),7.83(dd,J=8.5,2.2Hz,1H),7.68(s,1H),7.66(d,J=9.0Hz,1H ),7.58(d,J=2.0Hz,1H),7.44(dd,J=18.6,6.6Hz,1H),7.26–7.19(m,5H),4.89(s,2H),4.35(q,J=7.1Hz,2H),1.32(t,J=7.1Hz,3H).

[0161] 5-((N-(3-bromobenzyl)-4-chloro-3-nitrophenyl)sulfonyl)benzofuran-2-carboxylic acid ethyl ester (17)

[0162] For specific procedures, refer to the synthesis of intermediate 10. Yield: 74%, melting point: 139–142℃. 1 H NMR (400MHz, DMSO-d6) δ8.37(d,J=2.0Hz,1H),8.02(d,J=8.5Hz,1H),7.83(dd,J=8.5,2.1Hz,1H),7.69(d,J=8.0Hz,2H),7.60 (d,J=2.0Hz,1H),7.46–7.38(m,2H),7.25(dt,J=11.7,7.9Hz,3H),4.90(s,2H),4.36(q,J=7.1Hz,2H),1.33(t,J=7.1Hz,3H).

[0163] 5-((N-([1,1'-biphenyl]-4-ylmethyl)-4-chloro-3-nitrophenyl)sulfonamide) ethyl benzofuran-2-carboxylate (18)

[0164] For specific procedures, refer to the synthesis of intermediate 10. Yield: 82%, melting point: 187–190℃. 1 H NMR (400MHz, DMSO-d6) δ8.38(d,J=2.1Hz,1H),8.02(d,J=8.5Hz,1H),7.85(dd,J=8.5,2.2Hz,1H),7.68(d,J=8.5Hz,2H),7.63(d,J=2.0Hz,1H),7.58( t,J=8.4Hz,4H),7.42(t,J=7.6Hz,2H),7.34(d,J=8.3Hz,3H),7.30(dd,J= 9.0, 2.1Hz, 1H), 4.94 (s, 2H), 4.35 (q, J = 7.1Hz, 2H), 1.31 (t, J = 7.1Hz, 3H).

[0165] 5-((4-chloro-N-((4'-chloro-[1,1'-biphenyl]-4-yl)methyl)-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid ethyl ester (19)

[0166] For specific procedures, refer to the synthesis of intermediate 10. Yield: 30%, melting point: 185–187℃. 1 H NMR (400MHz, DMSO-d6) δ8.37(d,J=2.1Hz,1H),8.02(d,J=8.5Hz,1H),7.84(dd,J=8.5,2.1Hz,1H),7.68(d,J=9.1Hz,2H),7.65–7.60(m,3H),7.58(d ,J=8.2Hz,2H),7.47(d,J=8.5Hz,2H),7.35(d,J=8.2Hz,2H),7.29(dd,J=8 .7,2.1Hz,1H),4.94(s,2H),4.35(q,J=7.1Hz,2H),1.31(t,J=7.1Hz,3H).

[0167] 5-((4-chloro-N-((4'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid ethyl ester (20)

[0168] For specific procedures, refer to the synthesis of intermediate 10. Yield: 64%, melting point: 192–195℃. 1H NMR (400MHz, DMSO-d6) δ8.36(d,J=2.0Hz,1H),8.01(d,J=8.5Hz,1H),7.84(dd,J=8.5,2.1Hz,1H),7.67(d,J=9.1Hz,2H),7.62(d,J=2.0Hz,1 H),7.52(t,J=8.8Hz,4H),7.32–7.26(m,3H),6.97(d,J=8.7Hz,2H),4.92(s,2H),4.35(q,J=7.1Hz,2H),3.77(s,3H),1.31(t,J=7.1Hz,3H).

[0169] 5-((4-chloro-3-nitro-N-(4-phenoxybenzyl)phenyl)sulfonamide)benzofuran-2-carboxylic acid ethyl ester (21)

[0170] For specific procedures, refer to the synthesis of intermediate 10. Yield: 27%, melting point: 136–138℃. 1 H NMR (400MHz, DMSO-d6) δ8.36(d,J=2.1Hz,1H),8.01(d,J=8.5Hz,1H),7.84(d d,J=8.5,2.2Hz,1H),7.73–7.66(m,2H),7.57(d,J=2.0Hz,1H),7.36(t,J=8.0 Hz,2H),7.27–7.20(m,3H),7.12(t,J=7.4Hz,1H),6.92(d,J=7.8Hz,2H),6.8 7(d,J=8.6Hz,2H),4.87(s,2H),4.36(q,J=7.1Hz,2H),1.32(t,J=7.1Hz,3H).

[0171] 5-((4-chloro-N-((2',3'-dichloro-[1,1'-biphenyl]-4-yl)methyl)-3-nitrophenyl)sulfonamido)benzofuran-2-carboxylic acid ethyl ester (22)

[0172] For specific procedures, refer to the synthesis of intermediate 10. Yield: 29%, melting point: 152–155℃. 1 H NMR (400MHz, DMSO-d6) δ8.38(d,J=1.5Hz,1H),8.02(d,J=8.5Hz,1H),7.85(d,J=8.4Hz,1H),7.70(d,J=5. 8Hz,2H),7.68–7.60(m,2H),7.43–7.25(m,7H),4.98(s,2H),4.36(q,J=7.0Hz,2H),1.32(t,J=7.0Hz,3H).

[0173] 5-((N-([1,1'-biphenyl]-4-ylmethyl)-4-bromophenyl)sulfonamide)ethyl benzofuran-2-carboxylate (23)

[0174] For specific procedures, refer to the synthesis of intermediate 10. Yield: 68%, melting point: 180–183℃. 1 H NMR(400MHz,DMSO-d6)δ7.85(d,J=8.5Hz,2H),7.71–.63(m,2H),7.57(dd,J=13.2,8.5Hz,7H),7.41(t,J=7.6Hz,2H), 7.33(dd,J=13.1,7.6Hz,3H),7.23(dd,J=8.9,2.1Hz,1H),4.89(s,2H),4.34(q,J=7.1Hz,2H),1.31(t,J=7.1Hz,3H).

[0175] 5-(N-methyl-[1,1'-biphenyl]-4-sulfonamide)benzofuran-2-carboxylic acid ethyl ester (24)

[0176] For specific procedures, refer to the synthesis of intermediate 10. Yield: 57%, melting point: 108–111℃. 1 H NMR(400MHz, DMSO-d6)δ7.89(d,J=8.5Hz,2H),7.75(dd,J=14.7,5.3Hz,4H),7.62–7.56(m,3H),7.52(t,J=7.4Hz, 2H),7.45(t,J=7.3Hz,1H),7.29(dd,J=8.7,2.2Hz,1H),4.37(q,J=7.1Hz,2H),3.23(s,3H),1.33(t,J=7.1Hz,3H).

[0177] 5-(N-([1,1'-biphenyl]-4-ylmethyl)-[1,1'-biphenyl]-4-sulfonamido)ethyl benzofuran-2-carboxylate (25)

[0178] For specific procedures, refer to the synthesis of intermediate 10. Yield: 54%, melting point: 176–179℃. 1H NMR (400MHz, DMSO-d6) δ7.94(d,J=8.4Hz,2H),7.79(d,J=7.3Hz,2H),7.74(d,J=8.4H z,2H),7.69(s,1H),7.66(d,J=8.9Hz,1H),7.60(d,J=2.2Hz,2H),7.58(d,J=2.9Hz,2 H),7.56–7.51(m,3H),7.49–7.45(m,1H),7.44–7.36(m,4H),7.33(t,J=7.3Hz,1H),7 .27(dd,J=8.9,2.1Hz,1H),4.94(s,2H),4.34(q,J=7.1Hz,2H),1.30(t,J=7.1Hz,3H).

[0179] 5-(N-([1,1'-biphenyl]-3-ylmethyl)-[1,1'-biphenyl]-4-sulfonamido)ethyl benzofuran-2-carboxylate (26)

[0180] For specific procedures, refer to the synthesis of intermediate 10. Yield: 61%, melting point: 134–137℃. 1 H NMR (400MHz, DMSO-d6) δ7.94(d,J=8.5Hz,2H),7.81–7.73(m,4H),7.70–7.63(m,2H),7.60(d,J=2.0Hz,1H),7.57–7.50(m,5H),7.48(d,J =7.4Hz,2H),7.42(t,J=7.5Hz,2H),7.34(t,J=7.6Hz,2H),7.30–7.24(m,2H),4.97(s,2H),4.33(q,J=7.1Hz,2H),1.30(t,J=7.1Hz,3H).

[0181] 5-(N-((4'-chloro-[1,1'-biphenyl]-4-yl)methyl)-[1,1'-biphenyl]-4-sulfonamide) ethyl benzofuran-2-carboxylate (27)

[0182] For specific procedures, refer to the synthesis of intermediate 10. Yield: 70%, melting point: 144–146℃. 1H NMR (400MHz, DMSO-d6) δ7.94(d,J=8.5Hz,2H),7.79(d,J=7.3Hz,2H),7.73(d,J=8.5Hz,2H),7.70–7.60(m,5H),7.55(dd,J=14.9,7.9Hz,4H) ,7.47(dd,J=7.8,5.8Hz,3H),7.38(d,J=8.2Hz,2H),7.26(dd,J=8.9,2.2Hz,1H),4.94(s,2H),4.34(q,J=7.1Hz,2H),1.30(t,J=7.1Hz,3H).

[0183] 5-(N-((4'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-[1,1'-biphenyl]-4-sulfonamide) ethyl benzofuran-2-carboxylate (28)

[0184] For specific procedures, refer to the synthesis of intermediate 10. Yield: 61%, melting point: 194–196℃. 1 H NMR (400MHz, DMSO-d6) δ7.94(d,J=8.4Hz,2H),7.79(d,J=7.4Hz,2H),7.74(d,J =8.5Hz,2H),7.69(s,1H),7.65(d,J=9.0Hz,1H),7.60(d,J=2.0Hz,1H),7.57–7 .45(m,7H),7.33(d,J=8.2Hz,2H),7.26(dd,J=8.9,2.1Hz,1H),6.97(d,J=8.8H z,2H),4.92(s,2H),4.34(q,J=7.1Hz,2H),3.77(s,3H),1.31(t,J=7.1Hz,3H).

[0185] 5-(N-(4-(furan-2-yl)benzyl)-[1,1'-biphenyl]-4-sulfonamido)ethyl benzofuran-2-carboxylate (29)

[0186] For specific procedures, refer to the synthesis of intermediate 10. Yield: 3%, melting point: 186–188℃. 1H NMR (400MHz, DMSO-d6) δ7.93(d,J=8.4Hz,2H),7.78(d,J=7.4Hz,2H),7.74(d,J=8.4 Hz,2H),7.71–7.67(m,2H),7.63(d,J=8.9Hz,1H),7.60–7.51(m,5H),7.47(t,J=7.3H z,1H),7.31(d,J=8.2Hz,2H),7.22(dd,J=8.9,2.1Hz,1H),6.86(d,J=3.3Hz,1H),6. 55(dd,J=3.2,1.8Hz,1H),4.89(s,2H),4.34(q,J=7.1Hz,2H),1.30(t,J=7.1Hz,3H).

[0187] 5-(N-(4-(benzyloxy)benzyl)-[1,1'-biphenyl]-4-sulfonamido)benzofuran-2-carboxylic acid ethyl ester (30)

[0188] For specific procedures, refer to the synthesis of intermediate 10. Yield: 73%, melting point: 128–131℃. 1 H NMR (400MHz, DMSO-d6) δ7.92(d,J=8.4Hz,2H),7.78(d,J=7.5Hz,2H),7.71(d,J= 8.4Hz,2H),7.68(s,1H),7.63(d,J=8.9Hz,1H),7.57–7.50(m,3H),7.46(t,J=7.2 Hz, 1H), 7.34 (dt, J = 14.1, 7.4Hz, 5H), 7.18 (dd, J = 11.5, 5.2Hz, 3H), 6.87 (d, J = 8. 6Hz, 2H), 4.99 (s, 2H), 4.80 (s, 2H), 4.35 (q, J = 7.1Hz, 2H), 1.31 (t, J = 7.1Hz, 3H).

[0189] 5-(N-(4-phenoxybenzyl)-[1,1'-biphenyl]-4-sulfonamide)benzofuran-2-carboxylic acid ethyl ester (31)

[0190] For specific procedures, refer to the synthesis of intermediate 10. Yield: 49%, melting point: 145–147℃. 1H NMR (400MHz, DMSO-d6) δ7.93(d,J=8.5Hz,2H),7.78(d,J=7.3Hz,2H),7.73(d,J=8.4Hz,2H),7 .70(s,1H),7.66(d,J=8.9Hz,1H),7.54(dd,J=8.7,6.1Hz,3H),7.49–7.43(m,1H),7.38–7.31 (m,2H),7.27(d,J=8.6Hz,2H),7.21(dd,J=8.9,2.2Hz,1H),7.12(t,J=7.4Hz,1H),6.92(d,J= 7.7Hz,2H),6.87(d,J=8.6Hz,2H),4.86(s,2H),4.35(q,J=7.1Hz,2H),1.32(t,J=7.1Hz,3H).

[0191] 5-((4-chlorophenyl)sulfonamido)benzofuran-2-carboxylic acid (32)

[0192] Intermediate 3 (1.90 g, 5.00 mmol) was dissolved in a mixed solution of water (15.0 ml) and tetrahydrofuran (15.0 ml), followed by the addition of sodium hydroxide (0.8 g, 20.0 mmol) and stirring overnight at room temperature. After removing the organic solvent by vacuum distillation, 3M hydrochloric acid solution was added dropwise to the reaction system until pH = 2, during which a white crude solid precipitated. The crude product was filtered, dried, and purified by recrystallization from ethyl acetate to give 1.00 g of white solid, yield: 57%, melting point: 274–276 °C. 1 H NMR (400MHz, DMSO-d6) δ13.61(s,1H),10.37(s,1H),7.70(d,J=8.7Hz,2H),7.65–7.58(m,4H),7.48(s,1H),7.18(dd,J=8.9,1.6Hz,1H). 13 C NMR(101MHz,DMSO-d6)δ160.35,152.82,147.56,138.48,138.25,133.71,129.89,129.09,127.86,122.75,115.79,114.02,113.23.HRMS(AP-ESI)m / z Calcd forC 15 H 10 ClNO5S(MH) - 349.9895, found: 349.9895.

[0193] Example 2.5-((4-chloro-N-methylphenyl)sulfonamide)benzofuran-2-carboxylic acid (33)

[0194] The specific procedure is the same as that for the synthesis of compound 32, with a yield of 79% and a melting point of 208°C. 1 H NMR (400MHz, DMSO-d6) δ7.66(dd,J=18.6,9.9Hz,4H),7.53(d,J=2.2Hz,1H),7.52–7.48(m,2H),7.21(dd,J=8.9,2.2Hz,1H),3.20(s,3H). 13 C NMR(101MHz,DMSO-d6)δ160.42,154.08,148.31,138.77,137.25,135.04,129 .92,127.73,126.86,121.66,113.71,112.93,38.95.HRMS(AP-ESI)m / zCalcd for C 16 H 12 ClNO5S(MH) - 364.0051, found: 364.0056.

[0195] Example 3.5-((N-([1,1'-biphenyl]-4-ylmethyl)-4-chlorophenyl)sulfonamide)benzofuran-2-carboxylic acid (34)

[0196] The specific procedure is the same as that for the synthesis of compound 32, with a yield of 60% and a melting point of 214°C. 1 H NMR (400MHz, DMSO-d6) δ13.67(s,1H),7.71(d,J=8.7Hz,2H),7.68–7.63(m,3H),7.61(d,J=4.4Hz,2H),7.57(dd, J=7.6,4.5Hz,4H),7.42(t,J=7.6Hz,2H),7.34(dd,J=14.3,7.6Hz,3H),7.20(dd,J=8.8,2.1Hz,1H),4.90(s,2H). 13 C NMR(101MHz,DMSO-d6)δ160.23,154.26,147.78,139.87,138.77,136.83,135.62,134.72,130.06, 129.85,129.29,128.47,127.93,127.66,127.07,124.07,113.96,113.00,54.21.HRMS(AP-ESI)m / z Calcd for C 28 H 20 ClNO5S(MH) -516.0678, found: 516.0674.

[0197] Example 4.5-((N-([1,1'-biphenyl]-4-ylmethyl)-5-chloro-2,4-difluorophenyl)sulfonamide)benzofuran-2-carboxylic acid (35)

[0198] The specific procedure is the same as that for the synthesis of compound 32, with a yield of 49% and a melting point of 238–240 °C. 1 H NMR (400MHz, DMSO-d6) δ13.67 (s, 1H), 7.91 (dt, J = 15.0, 8.5Hz, 2H), 7.68–7. 55(m,7H),7.42(t,J=7.6Hz,2H),7.33(dd,J=13.6,5.0Hz,4H),5.00(s,2H). 13 C NMR(101MHz,DMSO-d6)δ160.21,154.39,147.92,139.93,135.46,134.08,132.36,129.33,128.53, 127.87,127.09,124.19,116.89,113.90,113.15,108.90,108.63,108.36,54.77.HRMS(AP-ESI)m / z Calcd forC 28 H 18 ClF2NO5S(MH) - 552.0490, found: 552.0498.

[0199] Example 5.5-((N-([1,1'-biphenyl]-4-ylmethyl)-6-chloropyridine)-3-sulfonyl)benzofuran-2-carboxylic acid (36)

[0200] The specific procedure is the same as that for the synthesis of compound 32, with a yield of 86% and a melting point of 205–207 °C. 1 H NMR (400MHz, DMSO-d6) δ13.65(s,1H),8.71(d,J=2.4Hz,1H),8.05(dd,J=8.4,2.6Hz,1H),7.80(d,J=8.4Hz,1H), 7.72–7.54(m,7H),7.42(t,J=7.6Hz,2H),7.34(dd,J=12.2,7.7Hz,3H),7.27(dd,J=8.9,2.2Hz,1H),4.95(s,2H). 13C NMR(101MHz,DMSO-d6)δ160.20,155.02,154.40,148.86,147.92,139.92,139.26,135.36,134.38, 134.10,129.31,128.50,127.87,127.08,125.79,124.27,113.90,113.19,54.42.HRMS(AP-ESI)m / z Calcd for C 27 H 19 ClN2O5S(MH) - 517.0630, found: 517.0636.

[0201] Example 6.5-((N-([1,1'-biphenyl]-4-ylmethyl)-4-(thiophen-2-yl)phenyl)sulfonamide)benzofuran-2-carboxylic acid (37)

[0202] The specific procedure is the same as that for the synthesis of compound 32, with a yield of 75% and a melting point of 246–250 °C. 1 H NMR (400MHz, DMSO-d6) δ13.66(s,1H),7.91(d,J=8.4Hz,2H),7.76(d,J=3.6Hz,1H),7.73(d,J=5.0Hz,1H),7.67(d, J=8.4Hz,2H),7.59(dt,J=12.7,9.4Hz,7H),7.37(qd,J=14.9,7.3Hz,5H),7.23(dd,J=8.4,2.8Hz,2H),4.92(s,2H). 13 C NMR(101MHz,DMSO-d6)δ160.21,154.22,147.81,141.76,139.99,139.75,138.61,136.42,135.78,134.98, 129.33,128.88,128.46,127.90,127.64,127.05,126.40,124.00,113.92,112.91,54.21.HRMS(AP-ESI)m / z Calcdfor C 32 H 23 NO5S2(MH) - 564.0945, found: 564.0965.

[0203] Example 7.5-((4-chloro-N-isobutyl-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid (38)

[0204] The specific procedure is the same as that for the synthesis of compound 32, with a yield of 16% and a melting point of 182–184 °C. 1 H NMR (400MHz, DMSO-d6) δ13.71(s,1H),8.23(d,J=2.1Hz,1H),7.96(d,J=8.5Hz,1H),7.73(dd,J=12.0,5.6Hz,2H),7.66 –7.61(m,2H),7.23(dd,J=8.8,2.1Hz,1H),3.44(d,J=7.2Hz,2H),1.45(dt,J=13.2,6.6Hz,1H),0.87(d,J=6.6Hz,6H). 13 C NMR(101MHz,DMSO-d6)δ160.30,154.49,148.09,137.92,134.56,133.48,132.45,130.38 ,128.29,127.96,125.02,124.04,113.92,113.33,58.31,26.84,20.03.HRMS(AP-ESI)m / z Calcd for C 19 H 17 ClN2O7S(MH) - 451.0372, found: 451.0375.

[0205] Example 8.5-((N-benzyl-4-chloro-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid (39)

[0206] For specific procedures, refer to the synthesis of compound 32. Yield: 9%, melting point: 190–192℃. 1 H NMR (400MHz, DMSO-d6) δ13.66(s,1H),8.36(d,J=2.1Hz,1H),8.01(d,J=8.5Hz,1H),7.83(dd,J=8.5,2 .2Hz,1H),7.62(d,J=8.9Hz,1H),7.59(s,1H),7.57(d,J=2.1Hz,1H),7.27–7.18(m,6H),4.89(s,2H). 13C NMR(101MHz,DMSO-d6)δ160.23,154.39,148.21,147.89,138.05,136.07,134.29,133.60,132.56, 130.56,128.93,128.65,128.13,127.75,125.18,124.33,113.88,113.13,54.87.HRMS(AP-ESI)m / z Calcd for C 22 H 15 ClN2O7S(MH) - 485.0216, found: 485.0217.

[0207] Example 9.5-((4-chloro-N-((4'-chloro-[1,1'-biphenyl]-4-yl)methyl)-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid (40)

[0208] The specific procedure is the same as that for the synthesis of compound 32, with a yield of 51% and a melting point of 170–172 °C. 1 H NMR (400MHz, DMSO-d6) δ8.37(d,J=2.1Hz,1H),8.02(d,J=8.5Hz,1H),7.85(dd,J=8.5,2.1Hz,1H),7.6 7–7.56(m,7H),7.47(d,J=8.6Hz,2H),7.35(d,J=8.2Hz,2H),7.26(dd,J=8.9,2.2Hz,1H),4.94(s,2H). 13 C NMR (101MHz, DMSO-d6) δ160.19,154.44,148.21,147.88,138.74,138.53,138.07,135.76,134.39,133.62,132. 86,132.58,130.61,129.34,128.67,127.81,127.14,125.19,124.30,113.93,113.21,54.59.HRMS(AP-ESI)m / z Calcd forC 28 H 18 Cl2N2O7S(MH) - 595.0139, found: 595.0149.

[0209] Example 10.5-((4-chloro-N-((4'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid (41)

[0210] The specific procedure is the same as that for the synthesis of compound 32, with a yield of 84% and a melting point of 210–212 °C. 1 H NMR (400MHz, DMSO-d6) δ13.61(s,1H),8.37(d,J=2.0Hz,1H),8.01(d,J=8.5Hz,1H),7.84(dd,J=8.5,2.1Hz,1H),7.64(d,J=9.0Hz,1H),7 .62–7.58(m,2H),7.57–7.48(m,4H),7.30(d,J=8.2Hz,2H),7.25(dd,J=8.9,2.1Hz,1H),6.97(d,J=8.7Hz,2H),4.92(s,2H),3.77(s,3H). 13 C NMR(101MHz,DMSO-d6)δ160.23,159.39,154.41,148.18,147.95,139.55,138.05,134.40,133.62,132.58,132.25,130 .60,129.28,128.56,128.08,127.81,126.61,125.20,124.30,114.77,113.87,113.18,55.59,54.60.HRMS(AP-ESI)m / z Calcd for C 29 H 21 ClN2O8S(MH) - 591.0634, found: 591.0647.

[0211] Example 11.5-((N-([1,1'-biphenyl]-4-ylmethyl)-4-chloro-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid (42)

[0212] The specific procedure is the same as that for the synthesis of compound 32, with a yield of 47% and a melting point of 208–211 °C. 1 H NMR (400MHz, DMSO-d6) δ13.62(s,1H),8.38(d,J=2.0Hz,1H),8.02(d,J=8.5Hz,1H),7.85(dd,J=8.5,2.1Hz,1 H),7.67–7.55(m,8H),7.43(t,J=7.6Hz,2H),7.34(t,J=8.7Hz,3H),7.27(dd,J=8.9,2.1Hz,1H),4.95(s,2H). 13C NMR (101MHz, DMSO-d6) δ160.24,154.42,148.21,147.91,139.90,138.01,135.32,134.37,133.62,132. 58,130.61,129.33,128.56,127.89,127.10,125.21,124.31,113.91,113.21,54.57.HRMS(AP-ESI)m / z Calcd for C 28 H 19 ClN2O7S(MH) - 561.0529, found: 561.0527.

[0213] Example 12.5-((N-([1,1'-biphenyl]-4-ylmethyl)-4-hydroxy-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid (43)

[0214] Intermediate 17 (0.60 g, 1.00 mmol) and potassium hydroxide (0.14 g, 2.50 mmol) were added to tert-butanol (8.0 mL) and stirred at 90 °C for 12 h. After cooling, the organic solvent was removed by vacuum distillation, and 3 M hydrochloric acid solution was added dropwise to the reaction system until pH = 2. During this process, a white crude solid precipitated. The crude product was dried and purified by Flash column chromatography to give 0.04 g of white solid, yield: 7%, melting point: 216 °C. 1 H NMR (400MHz, DMSO-d6) δ13.23(s,2H),8.09(d,J=2.0Hz,1H),7.67(d,J=8.8Hz,1H),7.60(dd,J=15.0,8.0Hz,5H) ,7.55(d,J=8.1Hz,2H),7.41(t,J=7.5Hz,2H),7.33(dd,J=11.5,7.8Hz,3H),7.25(t,J=7.8Hz,2H),4.88(s,2H). 13 C NMR(101MHz,DMSO-d6)δ160.27,156.63,154.27,147.79,139.97,139.73,137.23,135.67,134.88,133.82, 129.30,128.56,127.94,127.52,127.06,126.02,124.12,120.76,113.93,112.99,54.16.HRMS(AP-ESI)m / z Calcd for C 28 H 20 N₂O₈S(MH) -543.0868, found: 543.0870.

[0215] Example 13.5-((4-chloro-3-nitro-N-(4-phenoxybenzyl)phenyl)sulfonamide)benzofuran-2-carboxylic acid (44)

[0216] The specific procedure is the same as that for the synthesis of compound 32, with a yield of 66% and a melting point of 217–220 °C. 1 H NMR (400MHz, DMSO-d6) δ13.67(s,1H),8.37(d,J=2.1Hz,1H),8.02(d,J=8.5Hz,1H),7.84(dd,J=8.5,2.1Hz,1H),7.70 –7.53(m,3H),7.41–7.31(m,2H),7.29–7.19(m,3H),7.13(t,J=7.4Hz,1H),6.90(dd,J=20.2,8.2Hz,4H),4.87(s,2H). 13 C NMR(101MHz,DMSO-d6)δ160.23,156.74,154.44(s),148.19,147.95,138.22,134.28,133.62,132.55,130.96 ,130.51,128.70,127.81,125.15,124.44,124.06,119.22,118.83,113.88,113.16,54.46.HRMS(AP-ESI)m / z Calcd for C 28 H 19 ClN2O8S(MH) - 577.0478, found: 577.0488.

[0217] Example 14.5-((4-chloro-N-((2',3'-dichloro-[1,1'-biphenyl]-4-yl)methyl)-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid (45)

[0218] The specific procedure is the same as that for the synthesis of compound 32, with a yield of 39% and a melting point of 210–212 °C. 1 H NMR (400MHz, DMSO-d6) δ13.66(s,1H),8.38(d,J=2.0Hz,1H),8.02(d,J=8.5Hz,1H),7.85(dd, J=8.5,2.0Hz,1H),7.68–7.59(m,4H),7.42–7.32(m,5H),7.29(d,J=8.8Hz,2H),4.98(s,2H). 13CNMR(101MHz,DMSO-d6)δ160.31,154.43,148.19,142.26,138.58,138.15,136.30,134.49,133.63,132.68, 130.55,130.12,129.73,128.72,128.44,127.90,125.22,124.30,113.71,113.24,54.70.HRMS(AP-ESI)m / z Calcd for C 28 H 17 Cl3N2O7S(MH) - 628.9749, found: 628.9763.

[0219] Example 15.5-((N-([1,1'-biphenyl]-4-ylmethyl)-4-bromophenyl)sulfonamide)benzofuran-2-carboxylic acid (46)

[0220] The specific procedure is the same as that for the synthesis of compound 32, with a yield of 85% and a melting point of 192–194 °C. 1 H NMR(400MHz, DMSO-d6)δ13.73(s,1H),7.84(d,J=8.5Hz,2H),7.67–7.51(m,9H),7.41(t ,J=7.6Hz,2H),7.33(dd,J=12.9,7.7Hz,3H),7.18(dd,J=8.9,2.0Hz,1H),4.89(s,2H). 13 C NMR(101MHz,DMSO-d6)δ160.40,154.19,139.99,139.78,137.32,135.64,134.64,132.99, 129.91,129.29,128.26,128.09,127.07,123.95,113.47,112.93,54.22.HRMS(AP-ESI)m / z Calcdfor C 28 H 20 BrNO5S(MH) - 560.0173, found: 560.0199.

[0221] Example 16.5-([1,1'-biphenyl]-4-sulfonamide)benzofuran-2-carboxylic acid (47)

[0222] The specific procedure is the same as that for the synthesis of compound 32, with a yield of 82% and a melting point of >250℃. 1H NMR (400MHz, DMSO-d6) δ13.58(s,1H),10.36(s,1H),7.81(q,J=8.6Hz,4H),7.69(d,J=7.2Hz,2H),7.64–7. 57(m,2H),7.53(d,J=2.0Hz,1H),7.48(t,J=7.4Hz,2H),7.41(t,J=7.2Hz,1H),7.24(dd,J=8.9,2.2Hz,1H). 13 C NMR (101MHz, DMSO-d6) δ160.39,152.67,147.61,144.71,138.61,134.12,129. 55,129.03,127.84,127.49,122.36,115.18,113.96,113.17.HRMS(AP-ESI)m / z Calcd for C 21 H 15 NO5S(MH) - 392.0598, found: 392.0599.

[0223] Example 17.5-(N-methyl-[1,1'-biphenyl]-4-sulfonamide)benzofuran-2-carboxylic acid (48)

[0224] The specific procedure is the same as that for the synthesis of compound 32, with a yield of 79% and a melting point of >250℃. 1 H NMR (400MHz, DMSO-d6) δ7.89(d,J=8.4Hz,2H),7.76(d,J=7.3Hz,2H),7.58(d,J=8.4Hz,2H),7.48(ddd, J=16.9,14.8,7.2Hz,4H),7.35(d,J=2.1Hz,1H),7.02(dd,J=8.8,2.2Hz,1H),6.92(s,1H),3.21(s,3H). 13 C NMR(101MHz,DMSO-d6)δ162.37,157.46,153.12,144.92,138.68,136.45,135.31,1 29.64,129.08,128.71,127.63,124.08,120.40,112.16,107.33.HRMS(AP-ESI)m / z Calcd for C 22 H 17 NO5S(MH) - 406.0755, found: 406.0755.

[0225] Example 18.5-(N-([1,1'-biphenyl]-4-ylmethyl)-[1,1'-biphenyl]-4-sulfonamido)benzofuran-2-carboxylic acid (49)

[0226] The specific procedure is the same as that for the synthesis of compound 32, with a yield of 46% and a melting point of 208–210 °C. 1 H NMR (400MHz, DMSO-d6) δ7.94(d,J=8.5Hz,2H),7.79(d,J=7.3Hz,2H),7.74(d,J=8.4Hz,2H),7.57(ddd,J=14.6,12.0,5.8Hz,9H ),7.48(d,J=7.3Hz,1H),7.41(dd,J=13.9,6.1Hz,3H),7.37(s,1H),7.34(d,J=7.4Hz,1H),7.21(d,J=8.9Hz,1H),4.93(s,2H). 13 C NMR(101MHz,DMSO-d6)δ161.24,153.86,151.30,145.01,140.00,139.71,138.69,136.91,135.89,134.57, 129.67,129.29,128.63,128.40,128.02,127.57,127.06,123.50,112.64,111.53,54.25.HRMS(AP-ESI)m / z Calcd for C 34 H 25 NO5S(MH) - 558.1381, found: 558.1384.

[0227] Example 19.5-(N-([1,1'-biphenyl]-3-ylmethyl)-[1,1'-biphenyl]-4-sulfonamido)benzofuran-2-carboxylic acid (50)

[0228] The specific procedure is the same as that for the synthesis of compound 32, with a yield of 83% and a melting point of 206–210 °C. 1 H NMR (400MHz, DMSO-d6) δ13.62(s,1H),7.95(d,J=8.3Hz,2H),7.77(dd,J=11.2,8.1Hz,4H),7.66–7.51(m,8H),7.48(d,J= 7.4Hz,2H),7.43(t,J=7.6Hz,2H),7.35(t,J=7.3Hz,2H),7.28(d,J=7.6Hz,1H),7.23(dd,J=8.9,1.8Hz,1H),4.97(s,2H). 13C NMR(101MHz,DMSO-d6)δ160.32,154.19,148.13,145.09,140.68,140.25,138.69,137.29,136.98,134.97,129 .80,129.17,128.59,127.97,127.92,127.05,126.36,124.01,113.70,112.88,54.54.HRMS(AP-ESI)m / zCalcd for C 34 H 25 NO5S(MH) - 558.1381, found: 558.1370.

[0229] Example 20.5-(N-((4'-chloro-[1,1'-biphenyl]-4-yl)methyl)-[1,1'-biphenyl]-4-sulfonamide)benzofuran-2-carboxylic acid (51)

[0230] The specific procedure is the same as that for the synthesis of compound 32, with a yield of 87% and a melting point of 197–200 °C. 1 H NMR (400MHz, DMSO-d6) δ13.64(s,1H),7.94(d,J=8.4Hz,2H),7.79(d,J=7.5Hz,2H),7.74(d,J=8.4Hz,2H), 7.64–7.52(m,8H),7.47(t,J=6.5Hz,3H),7.39(d,J=8.2Hz,2H),7.24(dd,J=8.8,2.1Hz,1H),4.94(s,2H). 13 C NMR (101MHz, DMSO-d6) δ160.24,154.24,147.76,145.09,138.72,138.39,136.88,136.21,135.01,132. 82,129.64,129.24,128.89,127.91,127.60,127.06,124.00,113.95,112.91,54.24.HRMS(AP-ESI)m / z Calcd for C 34 H 25 NO5S(MH) - 558.1381, found: 558.1370.

[0231] Example 21.5-(N-((4'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-[1,1'-biphenyl]-4-sulfonamide)benzofuran-2-carboxylic acid (52)

[0232] The specific procedure is the same as that for the synthesis of compound 32, with a yield of 69% and a melting point of 206–209 °C. 1 H NMR (400MHz, DMSO-d6) δ13.68(s,1H),7.93(d,J=8.4Hz,2H),7.78(d,J=7.3Hz,2H),7.73(d,J=8.4Hz,2H),7.65–7 .42(m,10H),7.33(d,J=8.2Hz,2H),7.21(dd,J=8.9,2.0Hz,1H),6.97(d,J=8.8Hz,2H),4.91(s,2H),3.77(s,3H). 13 C NMR(101MHz,DMSO-d6)δ160.44,159.38,154.15,148.50,145.04,139.42,138.70,136.96,134.96,132.36,129 .65,129.19,128.62,128.36,128.15,126.56,123.90,114.79,113.44,112.84,55.61,54.25.HRMS(AP-ESI)m / z Calcdfor C 35 H 27 NO6S(MH) - 588.1486, found: 588.1480.

[0233] Example 22.5-(N-(4-(furan-2-yl)benzyl)-[1,1'-biphenyl]-4-sulfonamido)benzofuran-2-carboxylic acid (53)

[0234] The specific procedure is the same as that for the synthesis of compound 32, with a yield of 52% and a melting point of 230–233 °C. 1 H NMR (400MHz, DMSO-d6) δ13.61(s,1H),7.93(d,J=8.4Hz,2H),7.79(d,J=7.5Hz,2H),7.74(d,J=8.4Hz,2H),7.70(s,1H),7.56(dt,J=16.6,8.8 Hz,7H),7.47(t,J=7.3Hz,1H),7.32(d,J=8.2Hz,2H),7.18(dd,J=8.9,1.9Hz,1H),6.87(d,J=3.3Hz,1H),6.55(d,J=1.7Hz,1H),4.89(s,2H). 13CNMR(101MHz,DMSO-d6)δ160.28,154.19,153.10,145.05,143.41,138.69,136.87,135.67,134.85,130.03, 129.68,129.25,128.62,127.95,127.59,123.97,113.82,112.88,112.50,106.43,54.28.HRMS(AP-ESI)m / z Calcd for C 32 H 23 NO6S(MH) - 548.1173, found: 548.1167.

[0235] Example 23.5-(N-(4-(benzyloxy)benzyl)-[1,1'-biphenyl]-4-sulfonamide)benzofuran-2-carboxylic acid (54)

[0236] For specific procedures, refer to the synthesis of compound 32. Yield: 62%, melting point: 160–163℃. 1 H NMR (400MHz, DMSO-d6) δ13.63(s,1H),7.93(d,J=8.4Hz,2H),7.79(d,J=7.4Hz,2H),7.72(d,J=8.4Hz,2H),7.60(t,J=4.2Hz,2H),7. 51(ddd,J=23.8,14.8,7.2Hz,4H),7.42–7.28(m,5H),7.16(dd,J=10.2,5.3Hz,3H),6.88(d,J=8.6Hz,2H),5.00(s,2H),4.81(s,2H). 13 C NMR(101MHz,DMSO-d6)δ160.25,158.22,154.20,147.73,145.00,138.71,137.42,137.05,134.87,130.10,129 .65,129.16,128.64,128.21,127.91,127.57,124.10,115.10,113.96,112.81,69.64,54.01.HRMS(AP-ESI)m / z Calcd for C 35 H 27 NO6S(MH) - 588.1486, found: 588.1505.

[0237] Example 24.5-(N-(4-phenoxybenzyl)-[1,1'-biphenyl]-4-sulfonamide)benzofuran-2-carboxylic acid (55)

[0238] The specific procedure is the same as that for the synthesis of compound 32, with a yield of 91% and a melting point of 213–216 °C. 1 H NMR (400MHz, DMSO-d6) δ13.64(s,1H),7.93(d,J=8.4Hz,2H),7.79(d,J=7.4Hz,2H), 7.73(d,J=8.4Hz,2H),7.62(d,J=8.9Hz,2H),7.54(dd,J=8.6,6.3Hz,3H),7.47(t,J =7.3Hz,1H),7.35(t,J=7.9Hz,2H),7.27(d,J=8.5Hz,2H),7.18(dd,J=8.8,2.0Hz,1 H),7.12(t,J=7.4Hz,1H),6.92(d,J=7.9Hz,2H),6.88(d,J=8.5Hz,2H),4.87(s,2H). 13 C NMR (101MHz, DMSO-d6) δ160.26,156.86,156.55,154.25,147.80,145.04,138.70,137.02,134.93,131.48,130. 46,129.65,129.16,128.64,127.98,127.98,124.08,119.16,118.82,113.94,112.89,54.08.HRMS(AP-ESI)m / z Calcd for C 34 H 25 NO6S(MH) - 574.1330, found: 574.1340.

[0239] Example 25.5-((N-([1,1'-biphenyl]-4-ylmethyl)-3'-hydroxy-[1,1'-biphenyl])-4-sulfonamide)benzofuran-2-carboxylic acid (56)

[0240] Intermediate 23 (0.89 g, 1.50 mmol), 3-hydroxyphenylboronic acid (0.25 g, 1.80 mmol), tetrakis(triphenylphosphine palladium) (0.09 g, 10% weight), and potassium carbonate (0.63 g, 4.50 mmol) were added to 1,4-dioxane (16.0 mL) and water (4.0 mL), and refluxed at 115 °C for 12 hours under nitrogen protection. After cooling to room temperature, the organic solvent was removed by vacuum distillation, and the aqueous phase was adjusted to pH 2 with 3M hydrochloric acid solution and extracted with ethyl acetate. After removing the palladium catalyst by diatomaceous earth filtration and removing the organic solvent by vacuum distillation, a white crude solid was obtained. After purification by recrystallization from chloroform, 0.72 g of the white target product was obtained, yield: 83%, melting point: 188–190 °C. 1 H NMR (400MHz, DMSO-d6) δ13.65(s,1H),9.67(s,1H),7.86(d,J=8.4Hz,2H),7.72(d,J=8.4Hz,2H),7.59(dt,J=12.9,10.1 Hz,7H),7.37(ddd,J=30.7,15.4,7.6Hz,6H),7.27–7.15(m,2H),7.13(s,1H),6.87(dd,J=8.0,1.5Hz,1H),4.93(s,2H). 13 C NMR(101MHz,DMSO-d6)δ160.51,158.56,154.17,148.55,145.25,140.07,139.76,136.85,135.82,134.95,130.71, 129.29,128.48,128.34,127.83,127.05,123.92,118.29,116.24,114.34,113.44,112.85,54.28.HRMS(AP-ESI)m / z Calcd for C 34 H 25 NO6S(MH) - 574.1330, found: 574.1296.

[0241] Example 26.5-((N-benzyl-4-(hexylamino)-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid (57)

[0242] Intermediate 16 (0.78 g, 1.52 mmol), n-hexylamine (0.30 mL, 2.28 mmol), and triethylamine (0.30 mL, 2.28 mmol) were added to acetonitrile (25.0 mL), and the mixture was refluxed and stirred for 8 h. The organic solvent was removed under reduced pressure to obtain a yellow solid, which was washed with a small amount of ethyl acetate. The solid was dissolved in a mixed solution of water (5.0 mL) and tetrahydrofuran (5.0 mL), and sodium hydroxide (0.25 g, 6.30 mmol) was added. The mixture was stirred overnight at room temperature. After the reaction was complete, the organic solvent was removed under reduced pressure. The aqueous phase was adjusted to pH 2 with 3M hydrochloric acid solution, during which a yellow solid appeared. The crude product was obtained by filtration and purified by recrystallization from ethanol to obtain 0.43 g of yellow solid, yield: 51%, melting point: 154–156 °C. 1 H NMR (400MHz, DMSO-d6) δ8.59(t,J=5.4Hz,1H),8.21(d,J=1.8Hz,1H),7.57(d,J=9.0Hz,1H),7.51–7.41(m,2H),7.30–7.12(m,7H),7.0 8(d,J=8.8Hz,1H),4.80(s,2H),3.43(dd,J=12.8,6.6Hz,2H),1.63(dd,J=14.0,7.1Hz,2H),1.44–1.24(m,6H),0.89(d,J=6.6Hz,3H). 13 C NMR (101MHz, DMSO-d6) δ153.65,147.60,136.62,134.32,130.35,128.72,128.42,127.87,127.52,126. 96,123.33,116.00,112.40,109.91,54.51,43.06,31.36,28.56,26.44,22.49,14.33.HRMS(AP-ESI)m / z Calcd forC 28 H 29 N3O7S(MH) - 550.1654, found: 550.1656.

[0243] Example 27.5-((N-([1,1'-biphenyl]-4-ylmethyl)-4-(hexylamino)-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid (58)

[0244] The specific procedure is the same as that for the synthesis of compound 57, with a yield of 85% and a melting point of 204–206 °C. 1H NMR (400MHz, DMSO-d6) δ8.60(t,J=5.6Hz,1H),8.22(d,J=2.1Hz,1H),7.56(dd,J=15.2,7.6Hz,7H),7.48(s,1H),7.41(t,J=7.6Hz,2H),7.33 (dd,J=12.7,7.6Hz,3H),7.23(dd,J=14.4,5.5Hz,2H),4.86(s,2H),1.63(dd,J=14.3,7.1Hz,2H),1.41–1.27(m,6H),0.88(t,J=6.9Hz,3H). 13 C NMR(101MHz,DMSO-d6)δ160.61,154.11,149.14,147.62,139.99,139.70,135.75,134.96,134.27,130.35,129.29,128.20,1 27.87,127.57,127.03,123.87,123.14,116.02,112.89,54.09,43.05,31.37,28.55,26.45,22.50,14.33.HRMS(AP-ESI)m / z Calcdfor C 34 H 33 N3O7S(MH) - 626.1976, found: 626.1959.

[0245] Example 28.5-((N-methyl-4-((2-morpholinoethyl)amino)-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid (59)

[0246] The specific procedure is the same as that for the synthesis of compound 57, with a yield of 36% and a melting point of 244–246 °C. 1 H NMR (400MHz, DMSO-d6) δ8.73(s,1H),8.12(d,J=1.8Hz,1H),7.69(d,J=9.0Hz,1H),7.65(s,1H),7.59(d,J=1.7H z,1H),7.43(d,J=9.0Hz,1H),7.28(dd,J=12.1,5.4Hz,2H),3.81(s,6H),3.32(s,2H),3.18(s,3H),3.13(s,4H). 13C NMR(101MHz,DMSO-d6)δ160.34,154.12,147.91,147.21,137.57,134.24,131.18,127.67,12 7.30,121.86,116.07,113.98,112.90,64.46,54.35,52.02,38.90,37.85.HRMS(AP-ESI)m / z Calcd for C 22 H 24 N4O8S(MH) - 503.1242, found: 503.1244.

[0247] Example 29.5-((N-benzyl-3-nitro-4-((2-phenoxyethyl)amino)phenyl)sulfonamido)benzofuran-2-carboxylic acid (60)

[0248] For specific procedures, refer to the synthesis of compound 57. Yield: 10%, melting point: 170–173℃. 1 H NMR (400MHz, DMSO-d6) δ8.77(t,J=5.6Hz,1H),8.21(d,J=2.2Hz,1H),7.61(dd,J=9.1, 1.9Hz,1H),7.46(dd,J=9.4,5.3Hz,2H),7.37(d,J=9.3Hz,1H),7.31(dd,J=8.4,7.4Hz, 2H),7.23(dd,J=8.7,5.2Hz,4H),7.17(d,J=4.8Hz,2H),7.07(dd,J=8.8,2.0Hz,1H),6 .96(t,J=7.4Hz,3H),4.80(s,2H),4.27(t,J=5.3Hz,2H),3.87(dd,J=10.7,5.3Hz,2H). 13 C NMR(101MHz,DMSO-d6)δ158.60,153.70,147.77,136.56,134.30,130.65,130.07,128.80,128.66,128.12 ,127.41,127.11,123.97,123.56,121.46,116.39,114.99,112.46,66.34,54.48,42.52.HRMS(AP-ESI)m / z Calcd for C 30 H 25 N3O8S(MH) - 586.1290, found: 586.1291.

[0249] Example 30.5-((N-(3-bromobenzyl)-3-nitro-4-((2-phenoxyethyl)amino)phenyl)sulfonamide)benzofuran-2-carboxylic acid (61)

[0250] For specific procedures, refer to the synthesis of compound 57. Yield: 67%, melting point: 152–155℃. 1 H NMR (400MHz, DMSO-d6) δ8.77(t,J=5.4Hz,1H),8.23(d,J=1.7Hz,1H),7.59(d,J=9.1Hz,1H),7.51–7.41(m,3H),7.39–7.26(m,5H), 7.21(t,J=7.7Hz,1H),7.12–7.02(m,2H),6.96(t,J=7.3Hz,4H),4.81(s,2H),4.23(dt,J=33.8,5.1Hz,2H),3.87(d,J=5.4Hz,2H). 13 C NMR(101MHz,DMSO-d6)δ162.09,158.61,158.39,154.66,153.62,147.81,139.64,134.19,131.28,131.16,130.00,128.69 ,127.56,126.56,123.69,123.05,122.01,121.49,116.37,115.07,112.50,109.15,66.38,53.93,42.56.HRMS(AP-ESI)m / z Calcd for C 30 H 24 BrN3O8S(MH) - 664.0395, found: 664.0396.

[0251] Activity evaluation of target compounds

[0252] Experimental Example 1. Inhibition test of target compound on lymphocyte-specific tyrosine phosphatase

[0253] 1. [Materials]

[0254] Stock solution of the target compound (10 mM, dissolved in dimethyl sulfoxide), lymphocyte-specific tyrosine phosphatase, disodium p-nitrophenyl phosphate, dimethyl glutarate buffer, 96-well plate, Thermo Varioskan Flash full-wavelength multi-mode microplate reader.

[0255] 2. [Method]

[0256] Dilute the target compound stock solution to an appropriate concentration gradient with dimethyl glutate buffer and add to 96-well plates (30.0 μL per well). Add dimethyl glutate buffer (30.0 μL per well) to the blank control group. Dilute lymphocyte-specific tyrosine phosphatase to a working concentration of 25 μg / mL with dimethyl glutate buffer and add to 96-well plates (30.0 μL per well). Mix well and shake horizontally at low temperature for 20 min. Dilute disodium p-nitrophenyl phosphate to 4.4 mM with dimethyl glutate buffer and add to 96-well clear label plates (60.0 μL per well). Shake horizontally at 37°C for 10–15 min. Finally, add 1 M solution (120.0 μL per well) to terminate the reaction. Measure the absorbance at 405 nm after 5 min. Calculate the inhibition rate and IC50 using Prism GraphPad software and formulas. 50 Values; results are shown in Table 2.

[0257] Inhibition rate (%) = (A 空白组 -A 测试组 ) / A 空白组 *100;

[0258] Terminology Explanation:

[0259] mL: milliliter; μL: microliter; μg: microgram; mM: millimoles per liter; nm: nanometer; IC 50 Half-maximal inhibitory concentration (IC50); Substrate: disodium p-nitrophenyl phosphate;

[0260] Table 2. Results of in vitro inhibition of LYP by the target compound

[0261] Compound numbering <![CDATA[IC 50 (μM) a ]]> Compound numbering <![CDATA[IC 50 (μM) a ]]> 32 — 47 — 33 — 48 — 34 9.04±1.2 49 5.07±0.9 35 18.73±2.6 50 3.23±0.5 36 7.74±0.5 51 4.36±1.2 37 8.87±0.5 52 5.47±1.4 38 — 53 7.25±1.8 39 — 54 2.55±0.7 40 6.78±1.7 55 10.72±3.3 41 3.52±0.7 56 3.59±0.6 42 9.34±0.7 57 5.03±0.8 43 18.69±1.8 58 5.56±1.1 44 5.67±0.9 59 — 45 5.91±0.9 60 10.28±1.4 46 7.87±1.6 61 6.70±0.5

[0262] a The data in the table are the averages of three experiments; the values ​​after "±" represent the standard error.

[0263] Conclusion: The data in the table show that more than half of the target compounds exhibit good LYP inhibitory activity, IC50... 50 The inhibitory activity was less than 20 μM; among them, compounds 41, 50, 54 and 56 showed the best inhibitory activity, with IC50 values ​​less than 20 μM. 50 The concentration was less than 4 μM; the above-mentioned active compounds have LYP inhibitory activity, laying the foundation for the future development of highly active selective LYP inhibitors.

[0264] Experimental Example 2. In vivo anticancer assay of the target compound

[0265] 1. [Materials]

[0266] C57BL / 6 female mice (8 weeks old, 20-25g), PBS buffer (with 5% dimethyl sulfoxide added);

[0267] 2. [Method]

[0268] MC38 cells were subcutaneously injected into C57BL / 6J mice (n=5 per group). Once the tumors reached a certain size, compounds 41 and 54 were administered via gavage to the mice at a dose of 50 mg / kg twice daily. Mouse weight and tumor size were recorded every other day. Mice were sacrificed on day 14, and the tumors were isolated and weighed. Results are shown in the table below. Figure 1 .

[0269] Conclusion: From Figure 1 It can be seen that, compared with the control group (Vehecle), compounds 41 and 54 can inhibit the growth and weight of MC38 tumors after treatment, and the weight of mice increased slightly during the administration period. These results indicate that compounds 41 and 54 have in vivo anticancer effects.

[0270] The above-mentioned activity experimental data show that the benzofuran-based lymphocyte-specific tyrosine phosphatase inhibitors of the present invention have good LYP inhibitory activity and in vivo anticancer activity.

[0271] These compounds can be further studied for activity and drugability evaluation, and compounds with better activity can be developed for the preparation of drugs to prevent and treat tumors caused by abnormal expression or function of lymphocyte-specific tyrosine phosphatase.

Claims

1. Benzofuran-type lymphocyte-specific tyrosine phosphatase inhibitors are compounds with the general formula I, as well as their stereoisomers and pharmaceutically acceptable salts; In general formula I, X represents carbon atom and nitrogen atom; In general formula I, R1 represents a hydrogen atom, a halogen atom, or a nitro group; In general formula I, R2 represents a halogen atom, a hydroxyl group, a substituted secondary amine group, or a C5-C group. 15 Aryl, monoheterocyclic aryl containing 1-2 heteroatoms and having 5-6 ring atoms, wherein the substituent is selected from C1-C6 alkyl, monoheterocyclic C1-C6 alkyl containing 1-2 heteroatoms and having 3-6 ring atoms, wherein the heteroatoms are independently selected from O, S, and N; In general formula I, R3 represents a hydrogen atom or a halogen atom; In general formula I, R4 represents -(CH2)n1-Ph-Ar and -(CH2)n1-Ph-O-(CH2)n2-Ar; nl represents an integer between 0 and 4; n2 represents an integer from 0 to 4; Ph stands for phenyl; Ar represents C5-C with 1-2 substituents or without substitution. 15 The aryl group is a monoheterocyclic aryl group containing 1-2 heteroatoms and having 5-6 ring atoms, wherein the substituents are selected from halogen atoms and C1-C6 alkoxy groups, and the heteroatoms are independently selected from O.

2. The benzofuran-based lymphocyte-specific tyrosine phosphatase inhibitor as described in claim 1, characterized in that, In general formula I: X represents carbon and nitrogen atoms; R1 represents hydrogen atom, halogen atom, and nitro group; R2 represents a hydrogen atom, a halogen atom, a hydroxyl group, a substituted secondary amine group, a C5-C6 monocyclic aryl group, or a monoheterocyclic aryl group with 5-6 ring atoms containing 1-2 heteroatoms, wherein the substituent is selected from C1-C6 alkyl groups or monoheterocyclic aryl C1-C6 alkyl groups containing 5-6 ring atoms containing 1-2 heteroatoms, and the heteroatoms are independently selected from S; R3 represents a hydrogen atom or a halogen atom; R4 represents -(CH2)n1-Ph-Ar, -(CH2)n1-Ph-O-(CH2)n2- Ar; nl represents an integer between 0 and 4; n2 represents an integer from 0 to 4; Ph stands for phenyl; Ar represents a C5-C6 monocyclic aryl group with 1-2 substituents or no substituents, or a monoheterocyclic aryl group with 5-6 ring atoms containing 1-2 heteroatoms, wherein the substituents are selected from halogen atoms or C1-C6 alkoxy groups, and the heteroatoms are independently selected from O.

3. The benzofuran-based lymphocyte-specific tyrosine phosphatase inhibitor as described in claim 2, characterized in that, In general formula I: X represents carbon and nitrogen atoms; R1 represents hydrogen atom, chlorine atom, and nitro group; R2 represents a hydrogen atom, a chlorine atom, a bromine atom, a fluorine atom, a hydroxyl group, a substituted secondary amine group, or a phenyl or thiophene group with 1-3 substituents or without substitution; the substituents are selected from hydroxyl and n-hexyl groups; R3 represents a hydrogen atom and a fluorine atom; R4 represents -(CH2)n1-Ph-Ar, -(CH2)n1-Ph-O-(CH2)n2- Ar; nl represents an integer between 0 and 3; n2 represents an integer between 0 and 3; Ph stands for phenyl; Ar represents phenyl or furanyl groups with 1-2 substituents, or substituted or unsubstituted groups, wherein the substituents are selected from chlorine atoms or methoxy groups.

4. The benzofuran-based lymphocyte-specific tyrosine phosphatase inhibitor as described in claim 3, characterized in that, In general formula I: X represents carbon and nitrogen atoms; R1 represents hydrogen atom, chlorine atom, and nitro group; R2 represents a chlorine atom, a fluorine atom, a bromine atom, a hydroxyl group, a substituted secondary amino group, a phenyl group, or a thiophene group, wherein the substituent is selected from n-hexyl; R3 represents a hydrogen atom and a fluorine atom; R4 represents -(CH2)n1-Ph-Ar, -(CH2)n1-Ph-O-(CH2)n2- Ar; nl represents 1; n2 represents 0 or 1; Ph stands for phenyl; Ar represents phenyl or furanyl groups with 1-2 substituents, or substituted or unsubstituted groups, wherein the substituents are selected from chlorine atoms or methoxy groups.

5. The benzofuran-based lymphocyte-specific tyrosine phosphatase inhibitor as described in claim 4, characterized in that, In general formula I: 5-((N-([1,1'-biphenyl]-4-ylmethyl)-4-chlorophenyl)sulfonamido)benzofuran-2-carboxylic acid (34) 5-((N-([1,1'-biphenyl]-4-ylmethyl)-5-chloro-2,4-difluorophenyl)sulfonamide)benzofuran-2-carboxylic acid (35) 5-((N-([1,1'-biphenyl]-4-ylmethyl)-6-chloropyridine)-3-sulfonyl)benzofuran-2-carboxylic acid (36) 5-((N-([1,1'-biphenyl]-4-ylmethyl)-4-(thiophen-2-yl)phenyl)sulfonamide)benzofuran-2-carboxylic acid (37) 5-((4-chloro-N-((4'-chloro-[1,1'-biphenyl]-4-yl)methyl)-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid (40) 5-((4-chloro-N-((4'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid (41) 5-((N-([1,1'-biphenyl]-4-ylmethyl)-4-chloro-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid (42) 5-((N-([1,1'-biphenyl]-4-ylmethyl)-4-hydroxy-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid (43) 5-((4-chloro-3-nitro-N-(4-phenoxybenzyl)phenyl)sulfonamide)benzofuran-2-carboxylic acid (44) 5-((4-chloro-N-((2',3'-dichloro-[1,1'-biphenyl]-4-yl)methyl)-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid (45) 5-((N-([1,1'-biphenyl]-4-ylmethyl)-4-bromophenyl)sulfonamide)benzofuran-2-carboxylic acid (46) 5-(N-([1,1'-biphenyl]-4-ylmethyl)-[1,1'-biphenyl]-4-sulfonamido)benzofuran-2-carboxylic acid (49) 5-(N-([1,1'-biphenyl]-3-ylmethyl)-[1,1'-biphenyl]-4-sulfonamido)benzofuran-2-carboxylic acid (50) 5-(N-((4'-chloro-[1,1'-biphenyl]-4-yl)methyl)-[1,1'-biphenyl]-4-sulfonamide)benzofuran-2-carboxylic acid (51) 5-(N-((4'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-[1,1'-biphenyl]-4-sulfonamide)benzofuran-2-carboxylic acid (52) 5-(N-(4-(furan-2-yl)benzyl)-[1,1'-biphenyl]-4-sulfonamido)benzofuran-2-carboxylic acid (53) 5-(N-(4-(benzyloxy)benzyl)-[1,1'-biphenyl]-4-sulfonamide)benzofuran-2-carboxylic acid (54) 5-(N-(4-phenoxybenzyl)-[1,1'-biphenyl]-4-sulfonamide)benzofuran-2-carboxylic acid (55) 5-((N-([1,1'-biphenyl]-4-ylmethyl)-3'-hydroxy-[1,1'-biphenyl])-4-sulfonamide)benzofuran-2-carboxylic acid (56) 5-((N-([1,1'-biphenyl]-4-ylmethyl)-4-(hexylamino)-3-nitrophenyl)sulfonamide)benzofuran-2-carboxylic acid (58).

6. A method for preparing a benzofuran-based lymphocyte-specific tyrosine phosphatase inhibitor according to any one of claims 1-4, comprising the steps of: Ethyl 5-nitrobenzofuran-2-carboxylate was reduced by iron powder to generate intermediate 2. Under pyridine conditions, intermediate 2 reacted with substituted sulfonyl chloride to obtain intermediates 3-9. Subsequently, intermediates 3-9 under the action of sodium hydride under N-alkylation reaction with haloalkanes to obtain intermediates 11-14, 18-23, and 25-31. Finally, under different deethylation protection reaction conditions, the final products 34-37, 40-46, and 49-55 were obtained. Intermediate 23 reacts with 3-hydroxyphenylboronic acid via a Suzuki reaction to yield final product 56; Intermediate 18 undergoes a nucleophilic substitution reaction with a substituted primary amine, followed by deethyl ester protection under sodium hydroxide conditions to give final product 58; the synthetic route is as follows: Synthetic route Reagents and reaction conditions: (a) Iron powder, ammonium chloride, ethanol, room temperature; (b) Substituted sulfonyl chloride, pyridine, room temperature; (c) Halogenated hydrocarbon, sodium hydride, N,N-dimethylformamide, room temperature; (d) Sodium hydroxide, water, tetrahydrofuran, room temperature; (e) Potassium hydroxide, tert-butanol, 100 °C; (f) 3-hydroxyphenylboronic acid, tetra(triphenylphosphine palladium), potassium carbonate, 1,4-dioxane, water, nitrogen protection, reflux; (g)(i) Substituted primary amine, triethylamine, acetonitrile, reflux; (ii) Sodium hydroxide, water, tetrahydrofuran, room temperature; The substituted sulfonyl chlorides are p-4-chlorobenzenesulfonyl chloride, 5-chloro-2,4-difluorobenzenesulfonyl chloride, 6-chloropyridinesulfonyl chloride, 4-thiophenesulfonyl chloride, 4-chloro-3-nitrobenzenesulfonyl chloride, 4-bromobenzenesulfonyl chloride, 4-chlorobenzenesulfonyl chloride, and p-biphenylsulfonyl chloride; the halogenated hydrocarbons are 4-phenylbenzyl bromide, 3-phenylbenzyl bromide, 4'-chloro-4-phenylbenzyl bromide, 4'-methoxy-4-phenylbenzyl bromide, 4-furanylbenzyl bromide, 4-benzyloxybenzyl bromide, and 4-phenoxybenzyl bromide; and the substituted primary amine is n-hexylamine.

7. The use of the benzofuran derivative according to any one of claims 1-5, its stereoisomer or its chemically acceptable salt, in the preparation of a medicament for the prevention or treatment of cancer.

8. A pharmaceutical composition suitable for oral administration to mammals, comprising a benzofuran lymphocyte-specific tyrosine phosphatase inhibitor as described in any one of claims 1-5 and one or more pharmaceutically acceptable carriers or excipients.

9. A pharmaceutical composition suitable for parenteral administration to mammals, comprising a benzofuran lymphocyte-specific tyrosine phosphatase inhibitor as described in any one of claims 1-5 and one or more pharmaceutically acceptable carriers or excipients.

10. A pharmaceutical composition, characterized in that, The invention comprises a benzofuran-based lymphocyte-specific tyrosine phosphatase inhibitor according to any one of claims 1-5, its stereoisomer or a pharmaceutically acceptable salt thereof, and one or more therapeutically active substances, wherein the therapeutically active substances are selected from targeted antitumor drugs or chemotherapeutic agents, monoclonal antibody drugs, and immune cell therapy agents.

Citation Information

Patent Citations

  • Benzofuran derivatives, and preparation method and therapeutic action thereof

    CN105085450A

  • Benzo-heterocycle derivative, preparation method thereof and application of benzo-heterocycle derivative in medicine

    CN107619384A